Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 478 articles:
HTML format



Single Articles


    May 2024
  1. VICKERS AJ
    Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.0
    Eur Urol. 2024 May 25:S0302-2838(24)02385-6. doi: 10.1016/j.eururo.2024.
    PubMed    


  2. ULERI A, Baboudjian M, Diamand R, Ploussard G, et al
    Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Roder's Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer L
    Eur Urol. 2024 May 24:S0302-2838(24)02387-X. doi: 10.1016/j.eururo.2024.
    PubMed    


  3. ULERI A, Baboudjian M, Diamand R, Ploussard G, et al
    Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In
    Eur Urol. 2024 May 24:S0302-2838(24)02386-8. doi: 10.1016/j.eururo.2024.
    PubMed    


  4. VYNCKIER P, Annemans L, Raes S, Amrouch C, et al
    Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe.
    Eur Urol. 2024 May 23:S0302-2838(24)02378-9. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  5. WEINER AB, Kakani P, Armstrong AJ, Bossi A, et al
    Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review.
    Eur Urol. 2024 May 22:S0302-2838(24)02375-3. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  6. RAVI P, Xie W, Buyse M, Halabi S, et al
    Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
    Eur Urol. 2024 May 21:S0302-2838(24)02380-7. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  7. DALLA VOLTA A, Valcamonico F, Zivi A, Procopio G, et al
    Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
    Eur Urol. 2024 May 20:S0302-2838(24)02347-9. doi: 10.1016/j.eururo.2024.
    PubMed    


  8. JOSEFSSON A, Mansson M, Kohestani K, Spyratou V, et al
    Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GOTEBORG-2 Prostate Cancer Screening Trial.
    Eur Urol. 2024 May 20:S0302-2838(24)02379-0. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  9. BROOKMAN-MAY SD, Buyse M, Freedland SJ, Miladinovic B, et al
    Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer.
    Eur Urol. 2024 May 17:S0302-2838(24)02348-0. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  10. PADHANI AR, Lecouvet F, Petralia G, Koh DM, et al
    Re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. http
    Eur Urol. 2024 May 16:S0302-2838(24)02377-7. doi: 10.1016/j.eururo.2024.
    PubMed    


  11. GARCIA-RUIZ A, Macarro C, Mateo J, Perez-Lopez R, et al
    Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh's Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castrati
    Eur Urol. 2024 May 16:S0302-2838(24)02376-5. doi: 10.1016/j.eururo.2024.
    PubMed    


  12. FANKHAUSER CD, Wettstein MS, Wurnschimmel C, van Smeden M, et al
    Re: External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
    Eur Urol. 2024 May 15:S0302-2838(24)02340-6. doi: 10.1016/j.eururo.2024.
    PubMed    


  13. KRILAVICIUTE A, Kaaks R, Seibold P, de Vrieze M, et al
    Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.
    Eur Urol. 2024 May 15:S0302-2838(24)02358-3. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  14. STROOMBERG HV, Brasso K, Roder A
    Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.0
    Eur Urol. 2024 May 14:S0302-2838(24)02365-0. doi: 10.1016/j.eururo.2024.
    PubMed    


  15. MERSEBURGER AS, Chowdhury S, Bahl A
    Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study.
    Eur Urol. 2024 May 14:S0302-2838(24)02364-9. doi: 10.1016/j.eururo.2024.
    PubMed    


  16. CHIN JL
    Re: Incidence and Survival of Secondary Malignancies after External Beam Radiotherapy for Prostate Cancer in the SEER Database.
    Eur Urol. 2024 May 13:S0302-2838(24)02344-3. doi: 10.1016/j.eururo.2024.
    PubMed    


  17. KLUMPER N, Grunwald V, Hartmann A, Holzel M, et al
    The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer.
    Eur Urol. 2024 May 13:S0302-2838(24)02350-9. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  18. OKOLI S, Okoli O, Ding H, Adeleke S, et al
    Re: Actinium-225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer (WARMTH Act): A Multicentre, Retrospective Study.
    Eur Urol. 2024 May 11:S0302-2838(24)02352-2. doi: 10.1016/j.eururo.2024.
    PubMed    


  19. LIGHT A, Mayor N, Cullen E, Kirkham A, et al
    The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations.
    Eur Urol. 2024;85:466-482.
    PubMed     Abstract available


  20. ANAND M, Jain B, Aggarwal S
    Re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
    Eur Urol. 2024;85:e145.
    PubMed    


  21. HARTRAMPF PE, Rowe SP, Pomper MG, Higuchi T, et al
    Reply to Madhur Anand, Bela Jain, and Swati Aggarwal's Letter to the Editor re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-Specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
    Eur Urol. 2024;85:e146-e147.
    PubMed    


    April 2024
  22. TILKI D, van den Bergh RCN, Briers E, Van den Broeck T, et al
    EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Eur Urol. 2024 Apr 29:S0302-2838(24)02306-6. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  23. OST P, Siva S, Zilli T
    OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full?
    Eur Urol. 2024 Apr 27:S0302-2838(24)02307-8. doi: 10.1016/j.eururo.2024.
    PubMed    


  24. HU JC, Vickers AJ, Schaeffer EM
    Reply to Peter Ka-Fung Chiu, Xiaobo Wu, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate
    Eur Urol. 2024 Apr 26:S0302-2838(24)02314-5. doi: 10.1016/j.eururo.2024.
    PubMed    


  25. CHAKRABARTI D, Parker CC
    Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy.
    Eur Urol. 2024 Apr 26:S0302-2838(24)02308-X. doi: 10.1016/j.eururo.2024.
    PubMed    


  26. SAAD F, Hussain MHA, Tombal B, Fizazi K, et al
    Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of
    Eur Urol. 2024 Apr 20:S0302-2838(24)02264-4. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  27. HINDIE E, Champion C, Morgat C
    Re: Renu S. Eapen, James P. Buteau, Price Jackson, et al. Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. In press.
    Eur Urol. 2024 Apr 20:S0302-2838(24)02310-8. doi: 10.1016/j.eururo.2024.
    PubMed    


  28. CARDONA ORTEGON JD, Campana Perilla LA, Olarte Bermudez LM
    Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol 2024;85:105-11
    Eur Urol. 2024 Apr 20:S0302-2838(24)02315-7. doi: 10.1016/j.eururo.2024.
    PubMed    


  29. CORNFORD P, van den Bergh RCN, Briers E, Van den Broeck T, et al
    EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Eur Urol. 2024 Apr 12:S0302-2838(24)02254-1. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  30. GRABBERT M, Liakos N, Gratzke C
    Re: Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
    Eur Urol. 2024 Apr 11:S0302-2838(24)02258-9. doi: 10.1016/j.eururo.2024.
    PubMed    


  31. RUSH HL, Gilbert DC, Langley RE
    Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol 2023;84:579-87.
    Eur Urol. 2024 Apr 6:S0302-2838(24)02251-6. doi: 10.1016/j.eururo.2024.
    PubMed    


  32. ROY S, Fervaha G, Spratt DE, Sun Y, et al
    Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Eur Urol. 2024 Apr 2:S0302-2838(24)02239-5. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  33. ROY S, Saad F, Malone S, Agarwal N, et al
    Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study.
    Eur Urol. 2024;85:398-400.
    PubMed    


  34. O'CALLAGHAN M, Bulamu N, Gormly K, Jay A, et al
    Re: Prevalence of MRI Lesions in Men Responding to a GP-led Invitation for a Prostate Health Check: A Prospective Cohort Study.
    Eur Urol. 2024;85:395.
    PubMed    


    March 2024
  35. ENGLMAN C, Maffei D, Allen C, Kirkham A, et al
    PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.
    Eur Urol. 2024 Mar 30:S0302-2838(24)02232-2. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  36. LOGOTHETIS CJ, Hahn AW
    Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024
    Eur Urol. 2024 Mar 26:S0302-2838(24)02240-1. doi: 10.1016/j.eururo.2024.
    PubMed    


  37. WASSERSUG RJ, Schellhammer PF, Wibowo E
    Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7.
    Eur Urol. 2024 Mar 26:S0302-2838(24)02233-4. doi: 10.1016/j.eururo.2024.
    PubMed    


  38. WINDISCH O, Valerio M
    Re: Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience.
    Eur Urol. 2024 Mar 26:S0302-2838(24)02208-5. doi: 10.1016/j.eururo.2024.
    PubMed    


  39. DE MEERLEER G, Joniau S, Benijts J, Rans K, et al
    Oligometastatic Recurrent Prostate Cancer: Whether To Intensify Treatment or Not.
    Eur Urol. 2024 Mar 22:S0302-2838(24)02238-3. doi: 10.1016/j.eururo.2024.
    PubMed    


  40. BURGER M
    Re: First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Pro
    Eur Urol. 2024 Mar 22:S0302-2838(24)02205-X. doi: 10.1016/j.eururo.2024.
    PubMed    


  41. NIKITAS J, Rettig M, Shen J, Reiter R, et al
    Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
    Eur Urol. 2024 Mar 16:S0302-2838(24)00058-7. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  42. BABOUDJIAN M, Diamand R, Uleri A, Beauval JB, et al
    Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment?
    Eur Urol. 2024 Mar 16:S0302-2838(24)00071-X. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  43. CUSSENOT O, Chambaz A, Hamdy FC
    Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. Eur
    Eur Urol. 2024 Mar 15:S0302-2838(24)02139-0. doi: 10.1016/j.eururo.2024.
    PubMed    


  44. GARCIA-RUIZ A, Macarro C, Zacchi F, Morales-Barrera R, et al
    Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial.
    Eur Urol. 2024 Mar 14:S0302-2838(24)02133-X. doi: 10.1016/j.eururo.2024.
    PubMed    


  45. MOLLER F, Mansson M, Wallstrom J, Hellstrom M, et al
    Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Goteborg-2 Prostate Cancer Screening Trial.
    Eur Urol. 2024 Mar 14:S0302-2838(24)00052-6. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  46. WEBER M, Fendler WP, Ravi Kumar AS, Calais J, et al
    Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
    Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  47. VAUGIER L, Morvan C, Pasquier D, Buthaud X, et al
    Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07).
    Eur Urol. 2024 Mar 14:S0302-2838(24)02131-6. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  48. NICKOLS NG, Tsai S, Kane N, Tran S, et al
    Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.
    Eur Urol. 2024 Mar 14:S0302-2838(24)00079-4. doi: 10.1016/j.eururo.2024.
    PubMed    


  49. MONTIRONI R, Cimadamore A, Giannarini G, Crestani A, et al
    Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population.
    Eur Urol. 2024 Mar 14:S0302-2838(24)02141-9. doi: 10.1016/j.eururo.2024.
    PubMed    


  50. FODOR A, Brombin C, Chiti A, Di Muzio N, et al
    Re: Marcin Miszczyk, Pawel Rajawa, Takafumi Yanagisawa, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. In press. https://doi.org/1
    Eur Urol. 2024 Mar 12:S0302-2838(24)02140-7. doi: 10.1016/j.eururo.2024.
    PubMed    


  51. SARTOR O
    Prostate-specific Membrane Antigen-targeted Isotope Therapy: Inherent Challenges Owing to Heterogeneity and Clonal Evolution.
    Eur Urol. 2024;85:205-206.
    PubMed    


  52. PILATZ A, MacLennan S, van den Bergh RCN, Veeratterapillay R, et al
    Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. 2024;85:99-100.
    Eur Urol. 2024;85:313-314.
    PubMed    


    February 2024
  53. GOLIJANIN B, Mega A, Golijanin D
    Re: Ivo I. de Vos II, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Scr
    Eur Urol. 2024 Feb 29:S0302-2838(24)00081-2. doi: 10.1016/j.eururo.2024.
    PubMed    


  54. POPE B, Park G, Lau E, Belic J, et al
    Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer.
    Eur Urol. 2024 Feb 19:S0302-2838(24)00003-4. doi: 10.1016/j.eururo.2024.
    PubMed    


  55. FENG D, Wang J, Wu R, Li D, et al
    Re: Immune System and Intestinal Microbiota Determine Efficacy of Androgen Deprivation Therapy Against Prostate Cancer.
    Eur Urol. 2024 Feb 17:S0302-2838(24)00069-1. doi: 10.1016/j.eururo.2024.
    PubMed    


  56. DE VOS II, Remmers S, Roobol MJ
    Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin's Letter to the Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinui
    Eur Urol. 2024 Feb 17:S0302-2838(24)00057-5. doi: 10.1016/j.eururo.2024.
    PubMed    


  57. DEIVASIGAMANI S, Kotamarti S, Gupta RT, Polascik TJ, et al
    Re: Low Cancer Yield in PI-RADS 3 Upgraded to 4 by Dynamic Contrast-enhanced MRI: Is It Time To Reconsider Scoring Categorization?
    Eur Urol. 2024;85:180-181.
    PubMed    


  58. PREISSER F, Abrams-Pompe RS, Stelwagen PJ, Bohmer D, et al
    European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
    Eur Urol. 2024;85:164-170.
    PubMed     Abstract available


  59. MIAN BM
    Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise.
    Eur Urol. 2024;85:99-100.
    PubMed     Abstract available


    January 2024
  60. ARMSTRONG WR, Kishan AU, Booker KM, Grogan TR, et al
    Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
    Eur Urol. 2024 Jan 29:S0302-2838(24)00013-7. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  61. VICKERS AJ, Assel M, Cooperberg MR, Fine SW, et al
    Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer.
    Eur Urol. 2024 Jan 25:S0302-2838(24)00007-1. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available


  62. CHI KN, Armstrong AJ, Krause BJ, Herrmann K, et al
    Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2024 Jan 6:S0302-2838(23)03297-9. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


    December 2023
  63. LIU M, Chen P, Li T
    Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phas
    Eur Urol. 2023 Dec 21:S0302-2838(23)03293-1. doi: 10.1016/j.eururo.2023.
    PubMed    


  64. HUANG TB, Ding XF
    Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial, Eur Urol. In press. htt
    Eur Urol. 2023 Dec 16:S0302-2838(23)03294-3. doi: 10.1016/j.eururo.2023.
    PubMed    


  65. ALBERS P, van Poppel H
    Prostate Cancer Screening at its Best: The Swedish Organized Prostate Cancer Testing Program.
    Eur Urol. 2023 Dec 15:S0302-2838(23)03290-6. doi: 10.1016/j.eururo.2023.
    PubMed    


  66. CORPETTI M, Muller C, Beltran H, de Bono J, et al
    Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes.
    Eur Urol. 2023 Dec 15:S0302-2838(23)03278-5. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  67. FERNANDEZ-ZAPATA WF, Gandur Quiroga MN, Cardona Maya WD
    Re: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    Eur Urol. 2023 Dec 11:S0302-2838(23)03283-9. doi: 10.1016/j.eururo.2023.
    PubMed    


  68. RAGGI D, Cigliola A, Mercinelli C, Patane D, et al
    Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials.
    Eur Urol. 2023 Dec 11:S0302-2838(23)03260-8. doi: 10.1016/j.eururo.2023.
    PubMed    


  69. KAPLAN-MARANS E, Zhang TR, Hu JC
    Reply to Fabian Falkenbach, Francesco Sanguedolce, and Lars Budaus's Letter to the Editor re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European A
    Eur Urol. 2023;84:e151.
    PubMed    


  70. CAPOGROSSO P, Deho F, Salonia A, Briganti A, et al
    Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol 2023;83:534-47.
    Eur Urol. 2023;84:e146.
    PubMed    


  71. DJAILEB L, Armstrong WR, Thompson D, Gafita A, et al
    Presurgical (68)Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
    Eur Urol. 2023;84:588-596.
    PubMed     Abstract available


  72. SAAD F, Del Rosario P, Clarke NW
    Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespe
    Eur Urol. 2023 Dec 1:S0302-2838(23)03274-8. doi: 10.1016/j.eururo.2023.
    PubMed    


  73. BRATT O, Godtman RA, Jiborn T, Wallstrom J, et al
    Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men.
    Eur Urol. 2023 Dec 1:S0302-2838(23)03272-4. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  74. FALKENBACH F, Sanguedolce F, Budaus L
    Re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines. Eur Urol. 2023;84:44
    Eur Urol. 2023;84:e149-e150.
    PubMed    


    November 2023
  75. GIESEN A, Devlies W, Claessens F, Joniau S, et al
    Re: Abiraterone and Olaparib for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2023 Nov 27:S0302-2838(23)03273-6. doi: 10.1016/j.eururo.2023.
    PubMed    


  76. DING L, Yang B, Yao X
    Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phas
    Eur Urol. 2023 Nov 23:S0302-2838(23)03226-8. doi: 10.1016/j.eururo.2023.
    PubMed    


  77. MUN CHOW K, Zheng So W, Jie Lee H, Lee A, et al
    Corrigendum to "Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic R
    Eur Urol. 2023 Nov 14:S0302-2838(23)03213-X. doi: 10.1016/j.eururo.2023.
    PubMed    


  78. MOORE CM, Albertsen P
    When Is It Too Early To Start Prostate Cancer Screening? Reflections on the PROBASE Study Using Magnetic Resonance Imaging for Men Aged 45 Yr with Elevated Prostate-specific Antigen.
    Eur Urol. 2023 Nov 13:S0302-2838(23)03212-8. doi: 10.1016/j.eururo.2023.
    PubMed    


  79. HAMDY FC, Donovan JL
    Reply to Greg Shaw, John D. Kelly, and Monique J. Roobol's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:
    Eur Urol. 2023 Nov 8:S0302-2838(23)03218-9. doi: 10.1016/j.eururo.2023.
    PubMed    


  80. MISZCZYK M, Rajwa P, Yanagisawa T, Nowicka Z, et al
    The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.
    Eur Urol. 2023 Nov 7:S0302-2838(23)03209-8. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  81. TRUJILLO CG, Pena Rodriguez S, Diaz Ritter C
    Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol. 2023;83:534-47.
    Eur Urol. 2023;84:e116.
    PubMed    


  82. FENG T, Ren M, Zhou Z
    Re: Peter Fletcher, Marta De Santis, Simona Ippoliti, et al. Vector Prostate Biopsy: A Novel Magnetic Resonance Imaging/Ultrasound Image Fusion Transperineal Biopsy Technique Using Electromagnetic Needle Tracking Under Local Anaesthesia. Eur Urol 2023
    Eur Urol. 2023;84:e114.
    PubMed    


  83. LINDER S, Severson TM, van der Mijn KJC, Nevedomskaya E, et al
    Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.
    Eur Urol. 2023;84:455-460.
    PubMed     Abstract available


  84. WERNER RA, Hartrampf PE, Fendler WP, Serfling SE, et al
    Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.
    Eur Urol. 2023;84:491-502.
    PubMed     Abstract available


    October 2023
  85. DE VOS II, Remmers S, Hogenhout R, Roobol MJ, et al
    Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
    Eur Urol. 2023 Oct 31:S0302-2838(23)03207-4. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  86. EAPEN RS, Buteau JP, Jackson P, Mitchell C, et al
    Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.
    Eur Urol. 2023 Oct 25:S0302-2838(23)03087-7. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  87. SHARMA AD, Good DW, Alan McNeill S
    Re: Patient-reported Outcomes 12 Years after Localized Prostate Cancer Treatment.
    Eur Urol. 2023 Oct 19:S0302-2838(23)03157-3. doi: 10.1016/j.eururo.2023.
    PubMed    


  88. BOSCHHEIDGEN M, Albers P, Schlemmer HP, Hellms S, et al
    Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
    Eur Urol. 2023 Oct 18:S0302-2838(23)03158-5. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  89. HERLEMANN A, Cowan JE, Washington SL 3rd, Wong AC, et al
    Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
    Eur Urol. 2023 Oct 17:S0302-2838(23)03155-X. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  90. SORCE G, Mottrie A
    Re: Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study that Challenges the Dogma.
    Eur Urol. 2023 Oct 14:S0302-2838(23)03159-7. doi: 10.1016/j.eururo.2023.
    PubMed    


  91. GANDAGLIA G, Barletta F, Briganti A, Montorsi F, et al
    Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol 2
    Eur Urol. 2023 Oct 11:S0302-2838(23)03140-8. doi: 10.1016/j.eururo.2023.
    PubMed    


  92. KRAFFT U, Hadaschik BA, Luckerath K, Herrmann K, et al
    A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
    Eur Urol. 2023 Oct 11:S0302-2838(23)03149-4. doi: 10.1016/j.eururo.2023.
    PubMed    


  93. TOMBAL B, Collins S, Morgans AK, Hunsche E, et al
    Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
    Eur Urol. 2023 Oct 11:S0302-2838(23)03099-3. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  94. JUNG J, Kim JH
    Re: Casey Crump, Par Stattin, James D. Brooks, et al. Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study. Eur Urol 2023;84:263-72.
    Eur Urol. 2023 Oct 11:S0302-2838(23)03154-8. doi: 10.1016/j.eururo.2023.
    PubMed    


  95. HICKS RJ
    The Pythia Speaks on Prostate Cancer Diagnosis and Treatment.
    Eur Urol. 2023 Oct 11:S0302-2838(23)03148-2. doi: 10.1016/j.eururo.2023.
    PubMed    


  96. KISHAN AU, Valle LF, Marks LS
    Bullseye or Tip of the Iceberg: Magnetic Resonance Imaging-visible Disease in Radiorecurrent Prostate Cancer.
    Eur Urol. 2023 Oct 5:S0302-2838(23)03145-7. doi: 10.1016/j.eururo.2023.
    PubMed    


  97. COLE AP, Gupta N, Loeb S
    The Plant-based Prescription: How Dietary Change Can Improve Both Urological and Planetary Health.
    Eur Urol. 2023;84:357-358.
    PubMed     Abstract available


  98. HEIJNSDIJK EAM, de Koning HJ
    Wise Prostate-specific Antigen Testing Means a Limited, Risk-adjusted, and Personal Approach.
    Eur Urol. 2023;84:359-360.
    PubMed    


    September 2023
  99. LIGHT A, Kanthabalan A, Otieno M, Pavlou M, et al
    The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial.
    Eur Urol. 2023 Sep 29:S0302-2838(23)03089-0. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  100. LAMBERT E, Roupret M
    Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2023 Sep 27:S0302-2838(23)03137-8. doi: 10.1016/j.eururo.2023.
    PubMed    


  101. BEATRICI E, Labban M, Stone BV, Filipas DK, et al
    Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the USA from 2010 to 2020: Insights from the National Cancer Data Base.
    Eur Urol. 2023 Sep 25:S0302-2838(23)03088-9. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  102. PONTES-SILVA A
    Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023
    Eur Urol. 2023 Sep 25:S0302-2838(23)03094-4. doi: 10.1016/j.eururo.2023.
    PubMed    


  103. ILIE G, Rutledge RDH
    Reply to Andre Pontes-Silva's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Tr
    Eur Urol. 2023 Sep 22:S0302-2838(23)03091-9. doi: 10.1016/j.eururo.2023.
    PubMed    


  104. MAY M, Wolff I, Brookman-May SD
    Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023
    Eur Urol. 2023 Sep 22:S0302-2838(23)03095-6. doi: 10.1016/j.eururo.2023.
    PubMed    


  105. KLOTZ L
    Re: MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy.
    Eur Urol. 2023 Sep 22:S0302-2838(23)03080-4. doi: 10.1016/j.eururo.2023.
    PubMed    


  106. OPREA-LAGER DE, MacLennan S, Bjartell A, Briganti A, et al
    European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
    Eur Urol. 2023 Sep 22:S0302-2838(23)03092-0. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  107. ILIE G, Rutledge RDH
    Reply to Matthias May, Ingmar Wolff, and Sabine D. Brookman-May's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Un
    Eur Urol. 2023 Sep 22:S0302-2838(23)03093-2. doi: 10.1016/j.eururo.2023.
    PubMed    


  108. VAN POPPEL H, Roobol MJ, Chandran A
    Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U.
    Eur Urol. 2023 Sep 11:S0302-2838(23)03023-3. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  109. MICHEL MC
    Re: Genetically Adjusted PSA Levels for Prostate Cancer Screening.
    Eur Urol. 2023 Sep 9:S0302-2838(23)03081-6. doi: 10.1016/j.eururo.2023.
    PubMed    


  110. ROCCO B, Sighinolfi MC
    Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547-58.
    Eur Urol. 2023 Sep 6:S0302-2838(23)03069-5. doi: 10.1016/j.eururo.2023.
    PubMed    


    August 2023
  111. PAPACHRISTODOULOU A, Heidegger I, Virk RK, Di Bernardo M, et al
    Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression.
    Eur Urol. 2023 Aug 31:S0302-2838(23)03016-6. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  112. HAMDY FC, Donovan JL
    Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-
    Eur Urol. 2023 Aug 31:S0302-2838(23)03070-1. doi: 10.1016/j.eururo.2023.
    PubMed    


  113. LUPOLD SE, Isaacs WB, Luo J
    Aggravated Androgen Receptor Activity in Otherwise Indolent Prostate Cancer.
    Eur Urol. 2023 Aug 25:S0302-2838(23)03028-2. doi: 10.1016/j.eururo.2023.
    PubMed    


  114. ROY S, Sun Y, Morgan S, Malone S, et al
    Reply to Xiao Li, Zicheng Xu, and Feng Qi's Letter to the Editor re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Pro
    Eur Urol. 2023 Aug 16:S0302-2838(23)03021-X. doi: 10.1016/j.eururo.2023.
    PubMed    


  115. LI X, Xu Z, Qi F
    Re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur U
    Eur Urol. 2023 Aug 16:S0302-2838(23)03022-1. doi: 10.1016/j.eururo.2023.
    PubMed    


  116. GRAVAS S, Gacci M, Gratzke C, Herrmann TRW, et al
    Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms.
    Eur Urol. 2023;84:207-222.
    PubMed     Abstract available


  117. CHIU PK, Kasivisvanathan V, Gandaglia G
    Moving the Needle: Antibiotic Prophylaxis Is No Longer Required in the Era of Transperineal Prostate Biopsy.
    Eur Urol. 2023;84:154-155.
    PubMed     Abstract available


    July 2023
  118. POULIOT F, Emmett L
    Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now.
    Eur Urol. 2023 Jul 28:S0302-2838(23)02974-3. doi: 10.1016/j.eururo.2023.
    PubMed    


  119. WANG M, Wittenberg S, Cher ML, Van Til M, et al
    Does Urologist-level Utilization of Active Surveillance for Low-risk Prostate Cancer Correspond with Utilization of Active Surveillance for Small Renal Masses?
    Eur Urol. 2023 Jul 26:S0302-2838(23)02973-1. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  120. LAURITZEN PM, Jacewitz M, Baco E, Rud E, et al
    Re: Peter Ka-Fung Chiu, Veeru Kasivisvanathan, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Moving the Needle: Antibiotic Prophylaxis Is No Longer Required in the Era of Transperineal Pros
    Eur Urol. 2023 Jul 21:S0302-2838(23)02958-5. doi: 10.1016/j.eururo.2023.
    PubMed    


  121. BOESEN L
    Re: Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting.
    Eur Urol. 2023 Jul 19:S0302-2838(23)02967-6. doi: 10.1016/j.eururo.2023.
    PubMed    


  122. JIA AY, Kishan AU, Spratt DE
    Re: Dose-escalated Radiotherapy Alone or in Combination with Short-term Androgen Deprivation for Intermediate-risk Prostate Cancer: Results of a Phase III Multi-institutional Trial.
    Eur Urol. 2023 Jul 11:S0302-2838(23)02964-0. doi: 10.1016/j.eururo.2023.
    PubMed    


  123. DEIVASIGAMANI S, Kotamarti S, Rastinehad AR, Salas RS, et al
    Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
    Eur Urol. 2023 Jul 5:S0302-2838(23)02943-3. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  124. GANDAGLIA G, Pellegrino F, Golozar A, De Meulder B, et al
    Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data.
    Eur Urol. 2023 Jul 4:S0302-2838(23)02944-5. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  125. SURASI DS, Eiber M, Maurer T, Preston MA, et al
    Diagnostic Performance and Safety of Positron Emission Tomography with (18)F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
    Eur Urol. 2023 Jul 4:S0302-2838(23)02949-4. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  126. DAZA F, Diaz Ritter C, Badillo N
    Re: Michael S. Leapman, Cassandra L. Thiel, Ilyssa O. Gordon, et al. Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy. Eur Urol. 2023;83:463-71.
    Eur Urol. 2023;84:e12.
    PubMed    


  127. SCHAFER EJ, Jemal A, Wiese D, Sung H, et al
    Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA.
    Eur Urol. 2023;84:117-126.
    PubMed     Abstract available


    June 2023
  128. FENG F, Miladinovic B, Zhang K, Dignam JJ, et al
    Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies.
    Eur Urol. 2023 Jun 29:S0302-2838(23)02876-2. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  129. ARDOLINO LC, Dear R, Armstrong AJ, Gillessen S, et al
    Re: Timothee Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4-6.
    Eur Urol. 2023 Jun 22:S0302-2838(23)02893-2. doi: 10.1016/j.eururo.2023.
    PubMed    


  130. NGUYEN DD, Satkunasivam R, Wallis CJD
    Tackling Depression and Suicide Among Prostate Cancer Survivors: From Clinical Innovations to Continued Advocacy on the Upstream Social Determinants of Health.
    Eur Urol. 2023 Jun 21:S0302-2838(23)02891-9. doi: 10.1016/j.eururo.2023.
    PubMed    


  131. ABIDA W, Campbell D, Patnaik A, Bryce AH, et al
    Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
    Eur Urol. 2023 Jun 3:S0302-2838(23)02828-2. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  132. COLOMBA E, Jonas SF, Eymard JC, Delva R, et al
    A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
    Eur Urol. 2023 Jun 2:S0302-2838(23)02814-2. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  133. VAN DEN BROECK T, Joniau S, Everaerts W
    Adjuvant Docetaxel in Nonmetastatic Prostate Cancer: The King Is Dead, Long Live the King!
    Eur Urol. 2023 Jun 1:S0302-2838(23)02879-8. doi: 10.1016/j.eururo.2023.
    PubMed    


    May 2023
  134. CHANG D, Appu S, Siva S
    Re: Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    Eur Urol. 2023 May 31:S0302-2838(23)02832-4. doi: 10.1016/j.eururo.2023.
    PubMed    


  135. JIANG T, Valle LF, Kishan AU
    Contemporary Evaluation of Salvage Radiotherapy for Prostate Cancer: Radiotherapy Dose, Field Size, and Use of Hormone Therapy.
    Eur Urol. 2023 May 26:S0302-2838(23)02817-8. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  136. ILIE G, Rutledge RDH
    Reply to Zhipeng Mai, Weigang Yan, and Zhien Zhou's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curat
    Eur Urol. 2023 May 26:S0302-2838(23)02820-8. doi: 10.1016/j.eururo.2023.
    PubMed    


  137. MAI Z, Yan W, Zhou Z
    Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. 202
    Eur Urol. 2023 May 26:S0302-2838(23)02821-X. doi: 10.1016/j.eururo.2023.
    PubMed    


  138. GONZALEZ-PADILLA DA, Subiela JD
    Are PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not.
    Eur Urol. 2023 May 25:S0302-2838(23)02824-5. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  139. LOGOTHETIS CJ, Hahn AW
    Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome.
    Eur Urol. 2023 May 18:S0302-2838(23)02776-8. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  140. COOPERBERG MR
    Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    Eur Urol. 2023 May 17:S0302-2838(23)02805-1. doi: 10.1016/j.eururo.2023.
    PubMed    


  141. JUNG J, Kim JH
    Re: Loren K. Mell, Stephanie L. Pugh, Christopher U. Jones, et al. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Eur Urol. In press. https://doi
    Eur Urol. 2023 May 16:S0302-2838(23)02807-5. doi: 10.1016/j.eururo.2023.
    PubMed    


  142. BERGENGREN O, Pekala KR, Matsoukas K, Fainberg J, et al
    2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.
    Eur Urol. 2023 May 16:S0302-2838(23)02786-0. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  143. MAJUMDAR JR, Carlsson SV
    Re: A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial.
    Eur Urol. 2023 May 13:S0302-2838(23)02796-3. doi: 10.1016/j.eururo.2023.
    PubMed    


  144. GHAMANDE SS, Klaassen Z, Wallis CJD
    Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
    Eur Urol. 2023 May 12:S0302-2838(23)02794-X. doi: 10.1016/j.eururo.2023.
    PubMed    


  145. SARTOR O, Karrison TG, Sandler HM, Gomella LG, et al
    Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.
    Eur Urol. 2023 May 11:S0302-2838(23)02788-4. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  146. ARMSTRONG AJ, Iguchi T, Azad AA, Villers A, et al
    The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
    Eur Urol. 2023 May 11:S0302-2838(23)02723-9. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  147. SJOSTROM M, Bjartell A
    Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2023 May 11:S0302-2838(23)02793-8. doi: 10.1016/j.eururo.2023.
    PubMed    


  148. SUTERA P, Song Y, Van der Eecken K, Shetty AC, et al
    Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
    Eur Urol. 2023 May 10:S0302-2838(23)02790-2. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  149. CRUMP C, Stattin P, Brooks JD, Sundquist J, et al
    Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study.
    Eur Urol. 2023 May 9:S0302-2838(23)02787-2. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  150. BJERNER J, Bratt O, Aas K, Albertsen PC, et al
    Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium.
    Eur Urol. 2023 May 9:S0302-2838(23)02791-4. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  151. PLATA M, Cesar DR, Badillo N
    Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. In
    Eur Urol. 2023 May 3:S0302-2838(23)02782-3. doi: 10.1016/j.eururo.2023.
    PubMed    


  152. STRANNE J, Mottet N, Rouviere O
    Systematic Biopsies as a Complement to Magnetic Resonance Imaging-targeted Biopsies: "To Be or Not To Be"?
    Eur Urol. 2023;83:381-384.
    PubMed     Abstract available


  153. LEAPMAN MS, Thiel CL, Gordon IO, Nolte AC, et al
    Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy.
    Eur Urol. 2023;83:463-471.
    PubMed     Abstract available


  154. TERLIZZI M, Bossi A
    Re: The Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy (NRG Oncology/RTOG 0534 SPPORT): An International, Multicentre, Randomised Phase 3 Trial.
    Eur Urol. 2023;83:475.
    PubMed    


  155. SCHAFER H, Mayr S, Buttner-Herold M, Knorr K, et al
    Extensive (177)Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy-like Picture.
    Eur Urol. 2023;83:385-390.
    PubMed     Abstract available


    April 2023
  156. ILIE G, David Harold Rutledge R
    Reply to Mauricio Plata, Cesar Diaz Ritter, and Nicolas Badillo's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Un
    Eur Urol. 2023 Apr 29:S0302-2838(23)02781-1. doi: 10.1016/j.eururo.2023.
    PubMed    


  157. MARRA G, van Leenders GJLH, Zattoni F, Kesch C, et al
    Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review.
    Eur Urol. 2023 Apr 27:S0302-2838(23)02654-4. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  158. SHARMA AD, Lopez JF, Leiblich A, Leslie TA, et al
    Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    Eur Urol. 2023 Apr 26:S0302-2838(23)02712-4. doi: 10.1016/j.eururo.2023.
    PubMed    


  159. SOH PXY, Hayes VM
    Common Genetic Variants Associated with Prostate Cancer Risk: The Need for African Inclusion.
    Eur Urol. 2023 Apr 24:S0302-2838(23)02729-X. doi: 10.1016/j.eururo.2023.
    PubMed    


  160. REMMERS S, Bangma CH, Godtman RA, Carlsson SV, et al
    Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
    Eur Urol. 2023 Apr 21:S0302-2838(23)02709-4. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  161. BEIJE N, Abida W, Antonarakis ES, Castro E, et al
    PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
    Eur Urol. 2023 Apr 20:S0302-2838(23)02716-1. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  162. LARA PN JR, Mayerson E, Gertz E, Tangen C, et al
    Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.
    Eur Urol. 2023 Apr 19:S0302-2838(23)02715-X. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  163. HEMMINKI K, Ji J, Sundquist J
    Re: Mark N. Brook, Holly Ni Raghallaigh, Koveela Govindasami, et al. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. Eur Urol 2023;83:257-66.
    Eur Urol. 2023 Apr 13:S0302-2838(23)02718-5. doi: 10.1016/j.eururo.2023.
    PubMed    


  164. BROOK MN, Ni Raghallaigh H, Kote-Jarai Z, Eeles RA, et al
    Reply to Kari Hemminki, Jianguang Ji, and Jan Sundquist's Letter to the Editor re: Mark N. Brook, Holly Ni Raghallaigh, Koveela Govindasami, et al. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. Eur Ur
    Eur Urol. 2023 Apr 13:S0302-2838(23)02719-7. doi: 10.1016/j.eururo.2023.
    PubMed    


  165. CHOW KM, So WZ, Lee HJ, Lee A, et al
    Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-a
    Eur Urol. 2023 Apr 7:S0302-2838(23)02640-4. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  166. ADELEKE S, Ghose A, Boussios S
    Re: Pain and Health-related Quality of Life with Olaparib Versus Physician's Choice of Next-generation Hormonal Drug in Patients with Metastatic Castration-resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations (PROfound): An
    Eur Urol. 2023 Apr 7:S0302-2838(23)02702-1. doi: 10.1016/j.eururo.2023.
    PubMed    


  167. MORRIS MJ, Sartor O, de Bono JS, Fizazi K, et al
    Reply to Timothee Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022.
    Eur Urol. 2023 Apr 7:S0302-2838(23)02706-9. doi: 10.1016/j.eururo.2023.
    PubMed    


  168. MAYO ZS, Parker SM, Kilic SS, Weleff J, et al
    Disparities in Prostate Cancer Diagnoses Among Persons Experiencing Homelessness.
    Eur Urol. 2023 Apr 6:S0302-2838(23)02704-5. doi: 10.1016/j.eururo.2023.
    PubMed    


  169. DE VOS II, Meertens A, Hogenhout R, Remmers S, et al
    A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
    Eur Urol. 2023 Apr 5:S0302-2838(23)02669-6. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  170. NIK-AHD F, Cooperberg MR, Freedland SJ
    Reply to Sandra Patricia Garcia Nader, Sebastian Pena Rodriguez, and Cesar Alejandro Diaz Ritter's Letter to the Editor re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol
    Eur Urol. 2023;83:e104.
    PubMed    


  171. GARCIA NADER S, Pena Rodriguez S, Diaz Ritter CA
    Re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol. 2023;83:48-54.
    Eur Urol. 2023;83:e103.
    PubMed    


  172. NETTO GJ, Amin MB, Comperat EM, Gill AJ, et al
    Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.
    Eur Urol. 2023;83:301-303.
    PubMed     Abstract available


  173. VINCE RA JR, Sun Y, Mahal B, Ginsburg K, et al
    The Impact of a Statewide Active Surveillance Initiative: A Roadmap for Increasing Active Surveillance Utilization Nationwide.
    Eur Urol. 2023;83:307-310.
    PubMed     Abstract available


  174. CHENG Q, Butler W, Zhou Y, Zhang H, et al
    Erratum to "Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy" [Eur Urol 2022;81(5):446-55].
    Eur Urol. 2023 Apr 1:S0302-2838(23)02697-0. doi: 10.1016/j.eururo.2023.
    PubMed    


    March 2023
  175. GUO C, Figueiredo I, Gurel B, Neeb A, et al
    Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38].
    Eur Urol. 2023 Mar 22:S0302-2838(23)02645-3. doi: 10.1016/j.eururo.2023.
    PubMed    


  176. SEIFERT R, Emmett L, Rowe SP, Herrmann K, et al
    Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
    Eur Urol. 2023 Mar 17:S0302-2838(23)02574-5. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  177. KENIGSBERG AP, Ahdoot M, Turkbey B, Pinto PA, et al
    Re: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
    Eur Urol. 2023 Mar 10:S0302-2838(23)02631-3. doi: 10.1016/j.eururo.2023.
    PubMed    


  178. POSTEMA AW, Jager A, Mischi M, Salomon G, et al
    Re: Multiparametric Ultrasound Versus Multiparametric MRI to Diagnose Prostate Cancer (CADMUS): A Prospective, Multicentre, Paired-cohort, Confirmatory Study.
    Eur Urol. 2023 Mar 8:S0302-2838(23)02635-0. doi: 10.1016/j.eururo.2023.
    PubMed    


  179. ROY S, Sun Y, Morgan SC, Wallis CJD, et al
    Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial.
    Eur Urol. 2023 Mar 7:S0302-2838(23)02626-X. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  180. HABUCHI T
    Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study.
    Eur Urol. 2023 Mar 2:S0302-2838(23)02630-1. doi: 10.1016/j.eururo.2023.
    PubMed    


  181. SHEE K, Cowan JE, Balakrishnan A, Escobar D, et al
    Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort.
    Eur Urol. 2023 Mar 2:S0302-2838(23)02622-2. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  182. FLETCHER P, De Santis M, Ippoliti S, Orecchia L, et al
    Vector Prostate Biopsy: A Novel Magnetic Resonance Imaging/Ultrasound Image Fusion Transperineal Biopsy Technique Using Electromagnetic Needle Tracking Under Local Anaesthesia.
    Eur Urol. 2023;83:249-256.
    PubMed     Abstract available


  183. CIMADAMORE A, Lopez-Beltran A, Cheng L, Montironi R, et al
    Re: George J. Netto, Mahul B. Amin, Eva M. Comperat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.0
    Eur Urol. 2023;83:e84-e86.
    PubMed    


    February 2023
  184. CHEN F, Madduri RK, Rodriguez AA, Darst BF, et al
    Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.
    Eur Urol. 2023 Feb 27:S0302-2838(23)02561-7. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  185. ILIE G, Rendon R, Mason R, MacDonald C, et al
    A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial.
    Eur Urol. 2023 Feb 21:S0302-2838(23)02581-2. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  186. PONTES-SILVA A
    Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surge
    Eur Urol. 2023 Feb 14:S0302-2838(23)02583-6. doi: 10.1016/j.eururo.2023.
    PubMed    


  187. BERNARDINO R, Fleshner N
    Re: Sensitivity of Multiparametric MRI and Targeted Biopsy for Detection of Adverse Pathologies (Cribriform Gleason Pattern 4 and Intraductal Carcinoma): Correlation of Detected and Missed Prostate Cancer Foci with Whole Mount Histopathology.
    Eur Urol. 2023 Feb 13:S0302-2838(23)02573-3. doi: 10.1016/j.eururo.2023.
    PubMed    


  188. SCHILHAM MGM, Rijpkema M, Scheenen T, Hermsen R, et al
    Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia's Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly D
    Eur Urol. 2023 Feb 11:S0302-2838(23)02564-2. doi: 10.1016/j.eururo.2023.
    PubMed    


  189. OLIVIER T, Tsantoulis P, Prasad V
    Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
    Eur Urol. 2023 Feb 11:S0302-2838(23)02567-8. doi: 10.1016/j.eururo.2023.
    PubMed    


  190. MONTORSI F, Scuderi S, Briganti A, Gandaglia G, et al
    Re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80.
    Eur Urol. 2023 Feb 9:S0302-2838(23)02563-0. doi: 10.1016/j.eururo.2022.
    PubMed    


  191. KIM KM, Kim JH, Chung BI
    Re: Sigrid V. Carlsson, Rebecka Arnsrud Godtman, Carl-Gustav Pihl, et al. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Goteborg Randomized Populat
    Eur Urol. 2023 Feb 9:S0302-2838(23)02562-9. doi: 10.1016/j.eururo.2022.
    PubMed    


  192. VARATHARAJAN A, Olivier T, Prasad V
    Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?
    Eur Urol. 2023 Feb 9:S0302-2838(23)02565-4. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  193. FORTUIN A, van Asten J, Veltien A, Philips B, et al
    Small Suspicious Lymph Nodes Detected on Ultrahigh-field Magnetic Resonance Imaging (MRI) in Patients with Prostate Cancer with High Risk of Nodal Metastases: The First In-patient Study on Ultrasmall Superparamagnetic Iron Oxide-enhanced 7T MRI.
    Eur Urol. 2023 Feb 2:S0302-2838(23)00003-9. doi: 10.1016/j.eururo.2023.
    PubMed    


  194. BORGHESI M, Bauckneht M, Terrone C
    Re: Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography.
    Eur Urol. 2023;83:185-186.
    PubMed    


  195. POWELL K, Burns MC, Prasad V
    Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint.
    Eur Urol. 2023;83:101-102.
    PubMed     Abstract available


  196. STUDENT V JR, Tudos Z, Studentova Z, Cesak O, et al
    Effect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial.
    Eur Urol. 2023;83:154-162.
    PubMed     Abstract available


    January 2023
  197. BROOKMAN-MAY SD, May M
    Re: Prostate Cancer Polygenic Risk Score and Prediction of Lethal Prostate Cancer.
    Eur Urol. 2023 Jan 27:S0302-2838(23)00013-1. doi: 10.1016/j.eururo.2023.
    PubMed    


  198. MELL LK, Pugh SL, Jones CU, Nelson TJ, et al
    Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.
    Eur Urol. 2023 Jan 27:S0302-2838(23)00056-8. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available


  199. COMPERAT E, Oszwald A, Wasinger G
    Re: Percentage Gleason Pattern 4 and PI-RADS Score Predict Upgrading in Biopsy Grade Group 2 Prostate Cancer Patients Without Cribriform Pattern.
    Eur Urol. 2023 Jan 25:S0302-2838(23)00015-5. doi: 10.1016/j.eururo.2023.
    PubMed    


  200. SHAH TT, Kanthabalan A, Otieno M, Pavlou M, et al
    Corrigendum to "Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FOR
    Eur Urol. 2023 Jan 19:S0302-2838(23)00004-0. doi: 10.1016/j.eururo.2023.
    PubMed    


  201. SIRUFO MM, Ginaldi L, De Martinis M
    Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol 2022;82:341-51.
    Eur Urol. 2023 Jan 18:S0302-2838(22)02920-7. doi: 10.1016/j.eururo.2022.
    PubMed    


  202. MACLENNAN S, Azevedo N, Duncan E, Dunsmore J, et al
    Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
    Eur Urol. 2023 Jan 11:S0302-2838(22)02919-0. doi: 10.1016/j.eururo.2022.
    PubMed     Abstract available


  203. ALBERS P
    Re: Association of Prostate-specific Antigen Screening Rates with Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities: Prostate cancer screening needs not only to be well meant but also well done.
    Eur Urol. 2023 Jan 9:S0302-2838(22)02852-4. doi: 10.1016/j.eururo.2022.
    PubMed    


  204. LOEHR A, Chowdhury S, Abida W
    Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucapar
    Eur Urol. 2023 Jan 7:S0302-2838(22)02872-X. doi: 10.1016/j.eururo.2022.
    PubMed    


  205. BRATT O, Auvinen A
    Re: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
    Eur Urol. 2023 Jan 7:S0302-2838(22)02915-3. doi: 10.1016/j.eururo.2022.
    PubMed    


  206. CHANDRAN K, Grochot R, de Los Dolores Fenor De La Maza M, Yuan W, et al
    A Transgender Patient with Prostate Cancer: Lessons Learnt.
    Eur Urol. 2023 Jan 4:S0302-2838(22)02912-8. doi: 10.1016/j.eururo.2022.
    PubMed    


  207. LABBAN M, Trinh QD, D'Amico AV
    Re: Population-based Randomized Trial of Screening for Clinically Significant Prostate Cancer ProScreen: A Pilot Study.
    Eur Urol. 2023 Jan 4:S0302-2838(22)02916-5. doi: 10.1016/j.eururo.2022.
    PubMed    


  208. SEIBERT TM, Garraway IP, Plym A, Mahal BA, et al
    Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention.
    Eur Urol. 2023 Jan 4:S0302-2838(22)02870-6. doi: 10.1016/j.eururo.2022.
    PubMed     Abstract available


  209. QI F, Xu Z, Zou Q
    Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.0
    Eur Urol. 2023 Jan 3:S0302-2838(22)02873-1. doi: 10.1016/j.eururo.2022.
    PubMed    


  210. NIK-AHD F, Jarjour A, Figueiredo J, Anger JT, et al
    Prostate-Specific Antigen Screening in Transgender Patients.
    Eur Urol. 2023;83:48-54.
    PubMed     Abstract available


  211. CLARKE NW
    Following the Narrow Path.
    Eur Urol. 2023;83:27-28.
    PubMed    


  212. WEI Y, Huang H, Ye L
    Re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022:82:469-82.
    Eur Urol. 2023;83:e15.
    PubMed    


  213. RUBIN MA, Amin MB, Comperat E, Gill A, et al
    Reply to Yongbao Wei, Haijian Huang, and Liefu Ye's Letter to the Editor re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Pro
    Eur Urol. 2023;83:e16-e17.
    PubMed    


    December 2022
  214. TURKERI L, Ozen H
    Re: The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-stage Prostate Cancer.
    Eur Urol. 2022 Dec 20:S0302-2838(22)02854-8. doi: 10.1016/j.eururo.2022.
    PubMed    


  215. BANGMA CH
    Re: Modern Imaging in Prostate Cancer: Do We Treat Patients or Their Scans?
    Eur Urol. 2022 Dec 15:S0302-2838(22)02833-0. doi: 10.1016/j.eururo.2022.
    PubMed    


  216. YU EY, Piulats JM, Gravis G, Fong PCC, et al
    Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26].
    Eur Urol. 2022 Dec 15:S0302-2838(22)02844-5. doi: 10.1016/j.eururo.2022.
    PubMed    


  217. BROOK MN, Ni Raghallaigh H, Govindasami K, Dadaev T, et al
    Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study.
    Eur Urol. 2022 Dec 15:S0302-2838(22)02838-X. doi: 10.1016/j.eururo.2022.
    PubMed     Abstract available


  218. PLATA BELLO A, Touijer K
    Re: Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.
    Eur Urol. 2022 Dec 15:S0302-2838(22)02855-X. doi: 10.1016/j.eururo.2022.
    PubMed    


  219. BOGEMANN M, Shore ND, Smith MR, Tammela TLJ, et al
    Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022].
    Eur Urol. 2022 Dec 14:S0302-2838(22)02837-8. doi: 10.1016/j.eururo.2022.
    PubMed    


  220. CARLSSON SV, Godtman RA, Pihl CG, Vickers A, et al
    Corrigendum to "Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial" [Eur Urol (2022
    Eur Urol. 2022 Dec 8:S0302-2838(22)02839-1. doi: 10.1016/j.eururo.2022.
    PubMed    


  221. GILLESSEN S, Bossi A, Davis ID, de Bono J, et al
    Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
    Eur Urol. 2022 Dec 6:S0302-2838(22)02789-0. doi: 10.1016/j.eururo.2022.
    PubMed     Abstract available


    November 2022
  222. VILLERS A, Olivier J
    Re: Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.
    Eur Urol. 2022 Nov 26:S0302-2838(22)02699-9. doi: 10.1016/j.eururo.2022.
    PubMed    


  223. BUKAVINA L, Luckenbaugh AN, Hofman MS, Hope T, et al
    Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer.
    Eur Urol. 2022 Nov 17:S0302-2838(22)02780-4. doi: 10.1016/j.eururo.2022.
    PubMed     Abstract available


  224. ALBERTSEN PC
    Screening for Prostate Cancer with Prostate-specific Antigen: The Journey Continues.
    Eur Urol. 2022 Nov 10. pii: S0302-2838(22)02772.
    PubMed    


  225. HU M, Ye L
    Re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022;82:551-58.
    Eur Urol. 2022 Nov 7. pii: S0302-2838(22)02779.
    PubMed    


  226. SHENDEROV E, Antonarakis ES
    B7-H3 and Prostate Cancer: New Therapeutic Dance Partners.
    Eur Urol. 2022 Nov 5. pii: S0302-2838(22)02773.
    PubMed    


  227. YAO X, Duan C, Li B, Wu X, et al
    Re: Hilda A. de Barros, Matthias N. van Oosterom, Maarten L. Donswijk, et al. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Stu
    Eur Urol. 2022 Nov 2. pii: S0302-2838(22)02720.
    PubMed    


  228. CARLSSON SV, Arnsrud Godtman R, Pihl CG, Vickers A, et al
    Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial.
    Eur Urol. 2022 Nov 2. pii: S0302-2838(22)02715.
    PubMed     Abstract available


  229. XU P, Chen C, Chen B, Bi E, et al
    Long-term Follow-up of Detaenial Sigmoid Neobladder Reconstruction for Paediatric Patients with Bladder and Prostate Rhabdomyosarcoma: Technique and Results from a Single High-volume Centre.
    Eur Urol. 2022;82:543-550.
    PubMed     Abstract available


  230. MARTINI A, Mottet N, Montorsi F, Necchi A, et al
    A Plea for Economically Sustainable Evidence-based Guidelines.
    Eur Urol. 2022;82:449-451.
    PubMed     Abstract available


    October 2022
  231. FERGUSON EL, Kaouk JH
    Reply to Minxiong Hu and Liefu Ye's Letter to the Editor re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique.
    Eur Urol. 2022 Oct 25. pii: S0302-2838(22)02722.
    PubMed    


  232. AYATI N, Herrmann K, Fanti S, Murphy DG, et al
    More Accurate Imaging Is Not Stage Migration: Time To Move from "Hubble" to "Webb" in Hormone-sensitive Prostate Cancer.
    Eur Urol. 2022 Oct 21. pii: S0302-2838(22)02714.
    PubMed     Abstract available


  233. FERGUSON EL, Kaouk JH
    Reply to Shangqing Ren, Xu Hu, Kai Wang, Qian Lv, and Wang Dong's Letter to the Editor re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series
    Eur Urol. 2022 Oct 21. pii: S0302-2838(22)02717.
    PubMed    


  234. VANDEKERKHOVE G
    BRCA Reversion Mutations in Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2022 Oct 20. pii: S0302-2838(22)02708.
    PubMed    


  235. REN S, Hu X, Wang K, Lv Q, et al
    Re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022;82:551-58.
    Eur Urol. 2022 Oct 19. pii: S0302-2838(22)02716.
    PubMed    


  236. DE BARROS HA, van Oosterom MN, Donswijk ML, Hendrikx JJMA, et al
    Reply to Xiangyang Yao, Chen Duan, Bo Li, Xiaoliang Wu and Hua Xu's Letter to the Editor Re: Hilda A. de Barros, Matthias N. van Oosterom, Maarten L. Donswijk, et al. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Rec
    Eur Urol. 2022 Oct 19. pii: S0302-2838(22)02718.
    PubMed    


  237. LOEHR A, Hussain A, Patnaik A, Bryce AH, et al
    Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
    Eur Urol. 2022 Oct 12. pii: S0302-2838(22)02639.
    PubMed     Abstract available


  238. WANG B, Li C, Zheng X, Yao K, et al
    Re: Giorgio Gandaglia, Elio Mazzone, Armando Stabile, et al. Prostate-specific Membrane Antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymp
    Eur Urol. 2022 Oct 6. pii: S0302-2838(22)02696.
    PubMed    


  239. JACOBS MF, Greenberg SE
    Prostate Cancer Genomic Testing: When Sequencing Is Not Sufficient and Germline Testing Is Necessary.
    Eur Urol. 2022 Oct 5. pii: S0302-2838(22)02690.
    PubMed    


  240. MAXWELL KN, Pritchard CC
    Reply to Hela Sassi, Olivier Caron, and Etienne Rouleau's Letter to the Editor re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243-50.
    Eur Urol. 2022 Oct 3. pii: S0302-2838(22)02698.
    PubMed    


    September 2022
  241. HALL WA, Shoag J, Spratt DE
    Re: MRI-guided Focused Ultrasound Focal Therapy for Patients with Intermediate-risk Prostate Cancer: A Phase 2b, Multicentre Study.
    Eur Urol. 2022 Sep 29. pii: S0302-2838(22)02618.
    PubMed    


  242. DEVOS G, Tosco L, Baldewijns M, Gevaert T, et al
    ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
    Eur Urol. 2022 Sep 24. pii: S0302-2838(22)02638.
    PubMed     Abstract available


  243. SCHILHAM MGM, Rijpkema M, Scheenen T, Hermsen R, et al
    How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come.
    Eur Urol. 2022 Sep 24. pii: S0302-2838(22)02634.
    PubMed     Abstract available


  244. SASSI H, Caron O, Rouleau E
    Re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243-50: Off-core Li-Fraumeni Syndrome Spectrum Cancers: Increasing Interest for Prostate Cancer?
    Eur Urol. 2022 Sep 21. pii: S0302-2838(22)02632.
    PubMed    


  245. BARNETT ES, Schultz N, Stopsack KH, Lam ET, et al
    Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2022 Sep 16. pii: S0302-2838(22)02561.
    PubMed     Abstract available


  246. ZAPATERO A, Calvo FA, Gonzalez San-Segundo C, Alvarez A, et al
    Reply to Leonard P. Bokhorst and Berdine L. Heesterman's Words of Wisdom re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. Eur Urol. 2
    Eur Urol. 2022 Sep 14. pii: S0302-2838(22)02624.
    PubMed    


  247. TRUONG H, Breen K, Nandakumar S, Sjoberg DD, et al
    Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
    Eur Urol. 2022 Sep 14. pii: S0302-2838(22)02619.
    PubMed     Abstract available


  248. GUO C, Figueiredo I, Gurel B, Neeb A, et al
    B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
    Eur Urol. 2022 Sep 13. pii: S0302-2838(22)02633.
    PubMed     Abstract available


  249. DZIMITROWICZ HE, Armstrong AJ
    Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.
    Eur Urol. 2022 Sep 13. pii: S0302-2838(22)02621.
    PubMed    


  250. LEE DJ, Hausler R, Maxwell KN
    Reply to Joanne L. Dickinson, Georgea R. Foley, and Liesel M. FitzGerald's Letter to the Editor re: Daniel J. Lee, Ryan Hausler, Anh N. Le, et al. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. Eur Urol 2022;81:
    Eur Urol. 2022 Sep 13. pii: S0302-2838(22)02616.
    PubMed    


  251. OLIVIER T, Powell K, Prasad V
    Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial.
    Eur Urol. 2022 Sep 9. pii: S0302-2838(22)02613.
    PubMed     Abstract available


  252. BOGEMANN M, Shore ND, Smith MR, Tammela TLJ, et al
    Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
    Eur Urol. 2022 Sep 8. pii: S0302-2838(22)02532.
    PubMed     Abstract available


  253. LI H, Zhang Y, Xu H
    Reply to Adam G. Sowalsky, Stephen R. Plymate, Michael C. Haffner, Johann S. de Bono, and Adam Sharp's Letter to the Editor re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metast
    Eur Urol. 2022 Sep 7. pii: S0302-2838(22)02565.
    PubMed    


  254. DICKINSON JL, Foley GR, FitzGerald LM
    Re: Daniel J. Lee, Ryan Hausler, Anh N. Le, et al. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. Eur Urol 2022;81:559-67.
    Eur Urol. 2022 Sep 5. pii: S0302-2838(22)02617.
    PubMed    


  255. MONTORSI F, Bravi CA, Gandaglia G, Mottrie A, et al
    Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surge
    Eur Urol. 2022 Sep 2. pii: S0302-2838(22)02612.
    PubMed    


  256. BRISBANE WG, Priester AM, Ballon J, Kwan L, et al
    Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.
    Eur Urol. 2022;82:303-310.
    PubMed     Abstract available


    August 2022
  257. YU EY, Piulats JM, Gravis G, Fong PCC, et al
    Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
    Eur Urol. 2022 Aug 30. pii: S0302-2838(22)02554.
    PubMed     Abstract available


  258. SOWALSKY AG, Plymate SR, Haffner MC, de Bono JS, et al
    Re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86 AR-V7 is Rare in Horm
    Eur Urol. 2022 Aug 26. pii: S0302-2838(22)02563.
    PubMed    


  259. YANAGISAWA T, Rajwa P, Thibault C, Gandaglia G, et al
    Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2022 Aug 19. pii: S0302-2838(22)02551.
    PubMed     Abstract available


  260. CHANG D, Blanchard P, Siva S
    The Deep Blue of Prostate Cancer Metastasis Evolution: The LEVIATHAN Pooled Analysis.
    Eur Urol. 2022 Aug 19. pii: S0302-2838(22)02555.
    PubMed    


  261. MONTORSI F, Gandaglia G, Robesti D, Deho F, et al
    Re: Kathia De Man, Nick Van Laeken, Vanessa Schelfhout, et al. (18)F-PSMA-11 Versus (68)Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-
    Eur Urol. 2022 Aug 18. pii: S0302-2838(22)02557.
    PubMed    


  262. GRIVAS N, Lardas M, Espinos EL, Lam TB, et al
    Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review.
    Eur Urol. 2022 Aug 16. pii: S0302-2838(22)02540.
    PubMed     Abstract available


  263. KAOUK JH, Ferguson EL, Beksac AT, Zeinab MA, et al
    Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique.
    Eur Urol. 2022 Aug 12. pii: S0302-2838(22)02531.
    PubMed     Abstract available


  264. PETERS M, Eldred-Evans D, Kurver P, Falagario UG, et al
    Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert >/=3 Lesion: Development and Multinational External Validation of
    Eur Urol. 2022 Aug 10. pii: S0302-2838(22)02537.
    PubMed     Abstract available


  265. DASGUPTA P
    Re: Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer: The PANDA Challenge.
    Eur Urol. 2022 Aug 9. pii: S0302-2838(22)02543.
    PubMed    


  266. KESCH C, Hadaschik BA
    Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.
    Eur Urol. 2022 Aug 9. pii: S0302-2838(22)02546.
    PubMed    


  267. DORFF TB, Morgans AK
    A Path to Precision Medicine in Prostate Cancer: Learning from "Negative" Trials of Targeted Therapies.
    Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02527.
    PubMed    


  268. CARVALHO FLF, Mossanen M, Van Allen EM, Mouw KW, et al
    Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02534.
    PubMed    


  269. SONG Y, Du Y, Xu T
    Re: Matthew Mossanena, Filipe L.F. Carvalhoa, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Eur Urol. 2022 Aug 5. pii: S0302-2838(22)02530.
    PubMed    


  270. MA TM, Chu FI, Sandler H, Feng FY, et al
    Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).
    Eur Urol. 2022 Aug 4. pii: S0302-2838(22)02523.
    PubMed     Abstract available


  271. WASHINGTON SL
    We Must Change Our Approach to Racial Disparities in Prostate Cancer.
    Eur Urol. 2022 Aug 4. pii: S0302-2838(22)02529.
    PubMed    


  272. MEISSNER VH, Rauscher I, Schwamborn K, Neumann J, et al
    Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography.
    Eur Urol. 2022;82:156-160.
    PubMed     Abstract available


    July 2022
  273. BOSAS P, Zaleskis G, Characiejus D
    Re: Sylvia H.J. Jochems, Josef Fritz, Christel Haggstrom, Bengt Jarvholm, Par Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033.
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02478.
    PubMed    


  274. VILASECA A, Ribal MJ
    Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02526.
    PubMed    


  275. JOCHEMS SHJ, Stattin P, Stocks T
    Reply to Paulius Bosas, Gintaras Zaleskis, and Dainius Characiejus's Letter to the Editor re: Sylvia H.J. Jochems, Josef Fritz, Christel Haggstrom, Bengt Jarvholm, Par Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Deat
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02481.
    PubMed    


  276. MURTHY V, Chilukuri S, Maitre P
    Re: Pawel Rajwa, Benjamin Pradere, Giorgio Gandaglia, et al. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2022;82:82-96.
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02480.
    PubMed    


  277. LEVERIDGE M, Siemens DR
    Re: Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer.
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02528.
    PubMed    


  278. BOKHORST LP, Heesterman BL
    Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial.
    Eur Urol. 2022 Jul 25. pii: S0302-2838(22)02482.
    PubMed    


  279. GANDAGLIA G, Mazzone E, Stabile A, Pellegrino A, et al
    Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a
    Eur Urol. 2022 Jul 22. pii: S0302-2838(22)02417.
    PubMed     Abstract available


  280. SAMARATUNGA H, Delahunt B, Egevad L
    Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In pr
    Eur Urol. 2022;82:e15-e16.
    PubMed    


  281. PADHANI AR, Schoots IG, Giannarini G
    Re: Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.
    Eur Urol. 2022;82:143-144.
    PubMed    


  282. LENFANT L, Barret E, Roupret M, Rozet F, et al
    Transperineal Prostate Biopsy Is the New Black: What Are the Next Targets?
    Eur Urol. 2022;82:3-5.
    PubMed     Abstract available


  283. VAN LEEUWEN PJ, Emmett L
    (18)F-PSMA-11 as an Attractive (68)Ga-PSMA-11 Alternative for Prostate Cancer Imaging.
    Eur Urol. 2022 Jul 1. pii: S0302-2838(22)02416.
    PubMed    


    June 2022
  284. MARRA G, Agnello M, Giordano A, Soria F, et al
    Robotic Radical Prostatectomy for Prostate Cancer in Renal Transplant Recipients: Results from a Multicenter Series.
    Eur Urol. 2022 Jun 21. pii: S0302-2838(22)02400.
    PubMed     Abstract available


  285. SAAD F, de Bono J, Barthelemy P, Dorff T, et al
    Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
    Eur Urol. 2022 Jun 21. pii: S0302-2838(22)02407.
    PubMed     Abstract available


  286. KNIPPER S, Mehdi Irai M, Simon R, Koehler D, et al
    Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.
    Eur Urol. 2022 Jun 16. pii: S0302-2838(22)02408.
    PubMed     Abstract available


  287. VICKERS AJ
    Corrigendum to "Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer" [Eur Urol 2021;80:567-72].
    Eur Urol. 2022 Jun 14. pii: S0302-2838(22)02398.
    PubMed    


  288. DE MAN K, Van Laeken N, Schelfhout V, Fendler WP, et al
    (18)F-PSMA-11 Versus (68)Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.
    Eur Urol. 2022 Jun 8. pii: S0302-2838(22)02383.
    PubMed     Abstract available


  289. REDDY D, Ahmed HU
    Reply to Francesco Montorsi, Armando Stabile, Elio Mazzone, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focus
    Eur Urol. 2022 Jun 8. pii: S0302-2838(22)02412.
    PubMed    


  290. KISHAN AU, Spratt DE
    Reply to Yongfeng Lao, Yanan Wang, and Zhilong Dong's Letter to the Editor re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02410.
    PubMed    


  291. BEYER K, MacLennan S, Van Hemelrijck M
    Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resi
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02388.
    PubMed    


  292. CRABB SJ, Griffiths G, Dunkley D, Downs N, et al
    Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02393.
    PubMed     Abstract available


  293. LAO Y, Wang Y, Dong Z
    Re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02411.
    PubMed    


  294. ROCCO B, Sighinolfi MC, Coelho RF, Covas Moschovas M, et al
    Re: Trends in Incidence of Metastatic Prostate Cancer in the US.
    Eur Urol. 2022 Jun 2. pii: S0302-2838(22)02271.
    PubMed    


  295. MONTORSI F, Stabile A, Mazzone E, Gandaglia G, et al
    Re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol 2022;81:407-13
    Eur Urol. 2022 Jun 2. pii: S0302-2838(22)02394.
    PubMed    


    May 2022
  296. BURNS D, Anokian E, Saunders EJ, Bristow RG, et al
    Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.
    Eur Urol. 2022 May 31. pii: S0302-2838(22)02341.
    PubMed     Abstract available


  297. PLYM A, Zhang Y, Stopsack KH, Delcoigne B, et al
    A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer.
    Eur Urol. 2022 May 27. pii: S0302-2838(22)02342.
    PubMed     Abstract available


  298. LEI R, Li Y, Chen Y
    Re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 202
    Eur Urol. 2022 May 26. pii: S0302-2838(22)02387.
    PubMed    


  299. WEI Y, Ye D, Zhu Y
    Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.007.
    Eur Urol. 2022 May 19. pii: S0302-2838(22)02339.
    PubMed    


  300. SONG Y, Du Y, Xu T
    Re: Jiatong Zhou, Jie Ding, Jun Qi. Comparison of Typical Prostate Adenocarcinoma and Rare Histological Variant Prostate Cancer Showed Different Characteristics and Prognosis: A Surveillance, Epidemiology, and End Results Database Analysis. Eur Urol.
    Eur Urol. 2022 May 19. pii: S0302-2838(22)02334.
    PubMed    


  301. BERLIN A, Brierley J, Cornford P, Chung P, et al
    TNM Staging of Prostate Cancer: Challenges in Securing a Globally Applicable Classification.
    Eur Urol. 2022 May 10. pii: S0302-2838(22)02267.
    PubMed    


  302. RAKAUSKAS A, Valerio M, Roth B
    Re: Multiparametric Ultrasound Versus Multiparametric MRI To Diagnose Prostate Cancer (CADMUS): A Prospective, Multicentre, Paired-cohort, Confirmatory Study.
    Eur Urol. 2022 May 4. pii: S0302-2838(22)01815.
    PubMed    


  303. JOCHEMS SHJ, Fritz J, Haggstrom C, Jarvholm B, et al
    Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study.
    Eur Urol. 2022 May 3. pii: S0302-2838(22)01804.
    PubMed     Abstract available


  304. MARRA G, Stabile A, Gontero P, Montorsi F, et al
    Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In pr
    Eur Urol. 2022;81:e115-e116.
    PubMed    


  305. LEI Y, Han S, Xing N
    Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In pr
    Eur Urol. 2022;81:e121.
    PubMed    


    April 2022
  306. KISHAN AU, Wang X, Sun Y, Romero T, et al
    High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
    Eur Urol. 2022 Apr 22. pii: S0302-2838(22)01808.
    PubMed     Abstract available


  307. RAJWA P, Pradere B, Gandaglia G, van den Bergh RCN, et al
    Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2022 Apr 21. pii: S0302-2838(22)01802.
    PubMed     Abstract available


  308. GILLESSEN S, Armstrong A, Attard G, Beer TM, et al
    Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
    Eur Urol. 2022 Apr 18. pii: S0302-2838(22)01807.
    PubMed     Abstract available


  309. TURCO F, Armstrong A, Attard G, Beer TM, et al
    Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 2022].
    Eur Urol. 2022 Apr 16. pii: S0302-2838(22)01809.
    PubMed    


  310. YU EY, Kolinsky MP, Berry WR, Retz M, et al
    Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
    Eur Urol. 2022 Apr 6. pii: S0302-2838(22)01665.
    PubMed     Abstract available


  311. THOMAN ME, Salari K
    Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2022 Apr 5. pii: S0302-2838(22)01787.
    PubMed    


  312. DI LORENZO G, Buonerba C
    Re: Matthew R. Smith, Maha Hussain, Fred Saad, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2119115.
    Eur Urol. 2022 Apr 4. pii: S0302-2838(22)01675.
    PubMed    


  313. GAUTHE M, Sargos P, Benziane Ouaritini N, Barret E, et al
    Restaging of Patients with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy Using [(68)Ga]-PSMA-11 Positron Emission Tomography/Computed Tomography: Impact on Disease Management.
    Eur Urol. 2022;81:e87-e89.
    PubMed    


  314. LEI Y, Zhang Y, Xing N
    Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274-82.
    Eur Urol. 2022;81:e96-e97.
    PubMed    


  315. SOOD A, Jeong W, Palma-Zamora I, Abdollah F, et al
    Description of Surgical Technique and Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1-2b Study).
    Eur Urol. 2022;81:396-406.
    PubMed     Abstract available


    March 2022
  316. SHAH TT, Kanthabalan A, Otieno M, Pavlou M, et al
    Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy.
    Eur Urol. 2022 Mar 31. pii: S0302-2838(22)01664.
    PubMed     Abstract available


  317. HAO S, Heintz E, Ostensson E, Discacciati A, et al
    Corrigendum to "Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study" [Eur Urol 2022].
    Eur Urol. 2022 Mar 30. pii: S0302-2838(22)01796.
    PubMed    


  318. NYAME YA, Cooperberg MR, Cumberbatch MG, Eggener SE, et al
    Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care.
    Eur Urol. 2022 Mar 30. pii: S0302-2838(22)01677.
    PubMed     Abstract available


  319. BJARTELL A
    Re: Performance of a Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-derived Risk-stratification Tool for High-risk and Very High-risk Prostate Cancer.
    Eur Urol. 2022 Mar 29. pii: S0302-2838(22)01791.
    PubMed    


  320. PUSHKAR D, Govorov A
    Re: Survival After Radical Prostatectomy Versus Radiation Therapy in High-risk and Very High-risk Prostate Cancer.
    Eur Urol. 2022 Mar 29. pii: S0302-2838(22)01794.
    PubMed    


  321. WEI Y, Zhu Y, Ye D
    Re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. In press. https://doi.org/10.101
    Eur Urol. 2022 Mar 28. pii: S0302-2838(22)01801.
    PubMed    


  322. TURCO F, Smith M, Omlin A, Gillessen S, et al
    Reply to Yu Wei, Yao Zhu, and Dingwei Ye's Letter to the Editor re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Conse
    Eur Urol. 2022 Mar 28. pii: S0302-2838(22)01800.
    PubMed    


  323. MARTINI A, Ploussard G
    Re: Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.
    Eur Urol. 2022 Mar 25. pii: S0302-2838(22)01792.
    PubMed    


  324. CHEN K, McVey A, Kasivisvanathan V, Jenjitranant P, et al
    Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
    Eur Urol. 2022 Mar 25. pii: S0302-2838(22)01789.
    PubMed    


  325. WAGENSVELD IM, Osses DF, Groenendijk PM, Zijta FM, et al
    A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naive Men.
    Eur Urol. 2022 Mar 24. pii: S0302-2838(22)01673.
    PubMed     Abstract available


  326. KERKMEIJER LGW, Pos FJ, van der Heide UA, Israel B, et al
    Reply to Kamal Kant Sahu's Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial f
    Eur Urol. 2022 Mar 23. pii: S0302-2838(22)01674.
    PubMed    


  327. DE BARROS HA, van Oosterom MN, Donswijk ML, Hendrikx JJMA, et al
    Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study.
    Eur Urol. 2022 Mar 23. pii: S0302-2838(22)01672.
    PubMed     Abstract available


  328. HEIDEGGER I, Pircher A
    Re: Qing Cheng, William Butler, Yinglu Zhou, et al. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.039.
    Eur Urol. 2022 Mar 11. pii: S0302-2838(22)01667.
    PubMed    


  329. NG A, Khetrapal P, Kasivisvanathan V
    Is It PRIME Time for Biparametric Magnetic Resonance Imaging in Prostate Cancer Diagnosis?
    Eur Urol. 2022 Mar 8. pii: S0302-2838(22)01663.
    PubMed     Abstract available


  330. VAN DER POEL H
    Re: Radical Prostatectomy for Localized Prostate Cancer: 20-Year Oncological Outcomes from a German High-volume Center.
    Eur Urol. 2022 Mar 2. pii: S0302-2838(22)01658.
    PubMed    


    February 2022
  331. SAHU KK
    Re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press
    Eur Urol. 2022 Feb 26. pii: S0302-2838(22)01662.
    PubMed    


  332. ZHOU J, Ding J, Qi J
    Comparison of Typical Prostate Adenocarcinoma and Rare Histological Variant Prostate Cancer Showed Different Characteristics and Prognosis: A Surveillance, Epidemiology, and End Results Database Analysis.
    Eur Urol. 2022 Feb 24. pii: S0302-2838(22)01645.
    PubMed     Abstract available


  333. ALI A, Baena E
    The Needle in the Haystack: The Presence of Castrate-resistant Prostate Cancer Cells in Hormone-naive Prostate Cancer.
    Eur Urol. 2022 Feb 24. pii: S0302-2838(22)01609.
    PubMed    


  334. VICKERS AJ, Elfiky A, Freeman V, Roach M 3rd, et al
    Race, Biology, Disparities, and Prostate Cancer.
    Eur Urol. 2022 Feb 22. pii: S0302-2838(22)01646.
    PubMed    


  335. GRUNWALD V, Ohlmann CH, Hadaschik B
    Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol.
    Eur Urol. 2022 Feb 19. pii: S0302-2838(22)01648.
    PubMed    


  336. BEYER K, Moris L, Lardas M, Omar MI, et al
    Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium.
    Eur Urol. 2022 Feb 17. pii: S0302-2838(22)00085.
    PubMed     Abstract available


  337. TURCO F, Armstrong A, Attard G, Beer TM, et al
    What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
    Eur Urol. 2022 Feb 17. pii: S0302-2838(22)01650.
    PubMed     Abstract available


  338. MONTORSI F, Stabile A, Gandaglia G, Briganti A, et al
    Re: Jana S. Hopstaken, Joyce G.R. Bomers, Michiel J.P. Sedelaar, et al. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol 2022;81:5-33.
    Eur Urol. 2022 Feb 9. pii: S0302-2838(22)00078.
    PubMed    


  339. HEIJNSDIJK EAM, de Koning HJ
    Improved Harm/Benefit Ratio and Cost-effectiveness of Prostate Cancer Screening Using New Technologies.
    Eur Urol. 2022 Feb 4. pii: S0302-2838(22)00075.
    PubMed    


  340. REDDY D, Peters M, Shah TT, van Son M, et al
    Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.
    Eur Urol. 2022 Feb 2. pii: S0302-2838(22)00006.
    PubMed     Abstract available


  341. GODTMAN RA, Kollberg KS, Pihl CG, Mansson M, et al
    The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the Goteborg-1 Prostate Cancer Screening Trial.
    Eur Urol. 2022 Feb 1. pii: S0302-2838(22)00019.
    PubMed     Abstract available


  342. SAAD F, Small EJ, Feng FY, Graff JN, et al
    Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
    Eur Urol. 2022;81:184-192.
    PubMed     Abstract available


  343. MAZZONE E, Gandaglia G, Ploussard G, Marra G, et al
    Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups.
    Eur Urol. 2022;81:193-203.
    PubMed     Abstract available


    January 2022
  344. ZUMSTEG ZS
    Simultaneous Integrated Micro-boost: Reigniting the FLAME for Dose Escalation in Prostate Cancer?
    Eur Urol. 2022 Jan 30. pii: S0302-2838(22)00064.
    PubMed    


  345. BRAUN A, Abbosh PH
    Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy: A Rare Entity with Unique Genomic Features.
    Eur Urol. 2022 Jan 30. pii: S0302-2838(22)00067.
    PubMed    


  346. MARKT SC, Penney KL, Schumacher FR
    Finding a Place for Family History To Inform High-grade Prostate Cancer Risk.
    Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00066.
    PubMed    


  347. RASLAN M, Mercader C, Lamb AD
    Re: Prostate Cancer Screening Using a Combination of Risk-prediction, MRI, and Targeted Prostate Biopsies (STHLM3-MRI): A Prospective, Population-based, Randomised, Open-label, Non-inferiority Trial.
    Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00021.
    PubMed    


  348. WALZ J
    Re: Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: Results from the FLAME Randomized Phase III Trial.
    Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00016.
    PubMed    


  349. WITHINGTON J, Moore CM
    Active Surveillance for Prostate Cancer: Will Magnetic Resonance Imaging Help Us Address the Current Controversies in Traditional Surveillance Approaches?
    Eur Urol. 2022 Jan 28. pii: S0302-2838(22)00007.
    PubMed    


  350. MASON MD, van der Kwast TH, Mottet N, Oprea-Lager DE, et al
    Modern Imaging in Prostate Cancer: Do We Treat Patients, or Their Scans?
    Eur Urol. 2022 Jan 27. pii: S0302-2838(22)00003.
    PubMed     Abstract available


  351. HAO S, Heintz E, Ostensson E, Discacciati A, et al
    Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
    Eur Urol. 2022 Jan 27. pii: S0302-2838(21)02269.
    PubMed     Abstract available


  352. DI LALLA V, Kucharczyk MJ, Wyatt AW, Feng FY, et al
    Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer.
    Eur Urol. 2022 Jan 19. pii: S0302-2838(21)02287.
    PubMed     Abstract available


  353. CHENG Q, Butler W, Zhou Y, Zhang H, et al
    Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Eur Urol. 2022 Jan 17. pii: S0302-2838(22)00001.
    PubMed     Abstract available


  354. DARST BF, Hughley R, Pfennig A, Hazra U, et al
    A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02271.
    PubMed     Abstract available


  355. OZEN H, Turkeri L
    Re: Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-specific Mortality Results from the International Staging Collaboration for Cancer of the Prostate.
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02277.
    PubMed    


  356. DEVLIES W, Devos G, Decloedt H, Vansevenant B, et al
    Re: Molecular Features of Exceptional Response to Neoadjuvant Anti-androgen Therapy in High-risk Localized Prostate Cancer.
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02275.
    PubMed    


  357. SKOTHEIM RI, Axcrona U, Axcrona K
    Re: Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer.
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02280.
    PubMed    


  358. GREENBERG SE, Jacobs MF
    Continuing the Evolution of Germline Genetics in Prostate Cancer: Tailoring Testing To Enhance Patient Care.
    Eur Urol. 2022 Jan 10. pii: S0302-2838(21)02268.
    PubMed    


  359. FLESHNER K, Carlsson SV
    Re: Changes in Prostate-specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
    Eur Urol. 2022 Jan 10. pii: S0302-2838(21)02276.
    PubMed    


  360. SINGH J
    Re: Marc Sbizzera, Nicolas Morel-Journal, Alain Ruffion, et al. Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition. Eur Urol. In press.
    Eur Urol. 2022 Jan 7. pii: S0302-2838(21)02210.
    PubMed    


  361. MOROTE J, Diaz F, Celma A, Planas J, et al
    Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions.
    Eur Urol. 2022;81:124-125.
    PubMed    


  362. HOFMANN M, Huang E, Huynh LM, Kaler K, et al
    Retrospective Concomitant Nonrandomized Comparison of "Touch" Cautery Versus Athermal Dissection of the Prostatic Vascular Pedicles and Neurovascular Bundles During Robot-assisted Radical Prostatectomy.
    Eur Urol. 2022;81:104-109.
    PubMed     Abstract available


    December 2021
  363. CLEMENTS MB, Vertosick EA, Guerrios-Rivera L, De Hoedt AM, et al
    Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort.
    Eur Urol. 2021 Dec 31. pii: S0302-2838(21)02222.
    PubMed     Abstract available


  364. WILLEMSE PM, Davis NF, Grivas N, Zattoni F, et al
    Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
    Eur Urol. 2021 Dec 31. pii: S0302-2838(21)02215.
    PubMed     Abstract available


  365. GROEN VH, Haustermans K, Pos FJ, Draulans C, et al
    Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer.
    Eur Urol. 2021 Dec 22. pii: S0302-2838(21)02223.
    PubMed     Abstract available


  366. MOSSANEN M, Carvalho FLF, Muralidhar V, Preston MA, et al
    Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
    Eur Urol. 2021 Dec 22. pii: S0302-2838(21)02212.
    PubMed     Abstract available


  367. SBIZZERA M, Morel-Journel N, Carnicelli D, Ruffion A, et al
    Reply to Jas Singh's Letter to the Editor re: Marc Sbizzera, Nicolas Morel-Journel, Alain Ruffion, et al. Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Musc
    Eur Urol. 2021 Dec 18. pii: S0302-2838(21)02209.
    PubMed    


  368. GRUMMET J, Eggener S
    Re: NCCN Prostate Cancer Guidelines Version 1.2022 - September 10, 2021.
    Eur Urol. 2021 Dec 9. pii: S0302-2838(21)02201.
    PubMed    


  369. CASTRO E
    TP53: Another Piece of the Prostate Cancer Genetics Puzzle.
    Eur Urol. 2021 Dec 9. pii: S0302-2838(21)02199.
    PubMed    


  370. FASULO V, Zuradelli M, Lazzeri M
    Re: A Prospective Prostate Cancer Screening Programme for Men with Pathogenic Variants in Mismatch Repair Genes (IMPACT): Initial Results from an International Prospective Study.
    Eur Urol. 2021 Dec 9. pii: S0302-2838(21)02206.
    PubMed    


  371. SWAMI U, Sayegh N, Agarwal N
    Development of Novel Regimens Combining Immune Checkpoint Inhibitors and Radiation Therapy in Prostate Cancer.
    Eur Urol. 2021 Dec 8. pii: S0302-2838(21)02200.
    PubMed    


  372. MAXWELL KN, Cheng HH, Powers J, Gulati R, et al
    Inherited TP53 Variants and Risk of Prostate Cancer.
    Eur Urol. 2021 Dec 1. pii: S0302-2838(21)02139.
    PubMed     Abstract available


  373. ROCCO B, Sarchi L, Assumma S, Cimadamore A, et al
    Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique.
    Eur Urol. 2021;80:724-729.
    PubMed     Abstract available


    November 2021
  374. NGUYEN AT, Kamrava M
    Re: Jana S. Hopstaken, Joyce G.R. Bomers, Michiel J.P. Sedelaar, Massimo Valerio, Jurgen J. Futterer, Maroeska M. Rovers. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol. In
    Eur Urol. 2021 Nov 27. pii: S0302-2838(21)02159.
    PubMed    


  375. LANTZ A, Bock D, Akre O, Angenete E, et al
    Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiong's Letter to the Editor re: Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Ca
    Eur Urol. 2021 Nov 24. pii: S0302-2838(21)02150.
    PubMed    


  376. WILT TJ, Vo TN, Langsetmo L, Dahm P, et al
    Corrigendum re: "Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)" [Eur Urol 2020;77:713-24].
    Eur Urol. 2021 Nov 23. pii: S0302-2838(21)02157.
    PubMed    


  377. SO WZ, Wang Z, Tiong HY
    Re: Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021;80:650-60.
    Eur Urol. 2021 Nov 22. pii: S0302-2838(21)02140.
    PubMed    


  378. IMMERZEEL J, Israel B, Bomers J, Schoots IG, et al
    Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonance-Ultrasound Fusion Guided Biopsy Using Local Anesthesia.
    Eur Urol. 2021 Nov 16. pii: S0302-2838(21)02135.
    PubMed     Abstract available


  379. BACIARELLO G, Delva R, Gravis G, Tazi Y, et al
    Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
    Eur Urol. 2021 Nov 14. pii: S0302-2838(21)02117.
    PubMed     Abstract available


  380. PANSADORO V, Brassetti A
    Re: Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histolo
    Eur Urol. 2021 Nov 13. pii: S0302-2838(21)02125.
    PubMed    


  381. SCHMID HP, Hechelhammer L, Mullhaupt G
    Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer Under Active Surveillance: Cancer Prostate Embolisation, a Pilot Study.
    Eur Urol. 2021 Nov 9. pii: S0302-2838(21)02128.
    PubMed    


  382. DE KOUCHKOVSKY I, Chen HY, Ohliger MA, Wang ZJ, et al
    Hyperpolarized 1-[(13)C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer.
    Eur Urol. 2021 Nov 7. pii: S0302-2838(21)02116.
    PubMed    


  383. BELTRAN H, Morgans AK
    Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology.
    Eur Urol. 2021 Nov 3. pii: S0302-2838(21)02131.
    PubMed    


  384. ABREU AL, Kaneko M, Cacciamani GE, Lebastchi AH, et al
    Focal Therapy for Prostate Cancer: Getting Ready for Prime Time.
    Eur Urol. 2021 Nov 2. pii: S0302-2838(21)02073.
    PubMed    


  385. KAZYBAY B, Xie Y
    Re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.06.024.
    Eur Urol. 2021;80:e115-e116.
    PubMed    


  386. COELINGH BENNINK HJT, Foidart JM, Debruyne FMJ
    Reply to Bexultan Kazybay and Yingqiu Xie's Letter to the Editor re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy. Eur Urol. In press
    Eur Urol. 2021;80:e117-e118.
    PubMed    


    October 2021
  387. VAN POPPEL H, Roobol MJ
    Reply to Takeshi Takahashi's Letter to the Editor re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association
    Eur Urol. 2021 Oct 28. pii: S0302-2838(21)02072.
    PubMed    


  388. TAKAHASHI T
    Re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
    Eur Urol. 2021 Oct 26. pii: S0302-2838(21)02071.
    PubMed    


  389. GRAF RP, Fisher V, Mateo J, Gjoerup OV, et al
    Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2021 Oct 26. pii: S0302-2838(21)02060.
    PubMed     Abstract available


  390. LEE DJ, Hausler R, Le AN, Kelly G, et al
    Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
    Eur Urol. 2021 Oct 25. pii: S0302-2838(21)02059.
    PubMed     Abstract available


  391. SBIZZERA M, Morel-Journel N, Ruffion A, Crouzet S, et al
    Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition.
    Eur Urol. 2021 Oct 19. pii: S0302-2838(21)02041.
    PubMed     Abstract available


  392. OST P, Siva S, Zilli T
    Everything But the Kitchen Sink: Comprehensive Nodal Irradiation with Androgen Deprivation in OLIGOPELVIS.
    Eur Urol. 2021;80:415-416.
    PubMed    


  393. BIANCHI L, Chessa F, Angiolini A, Cercenelli L, et al
    The Use of Augmented Reality to Guide the Intraoperative Frozen Section During Robot-assisted Radical Prostatectomy.
    Eur Urol. 2021;80:480-488.
    PubMed     Abstract available


  394. WURNSCHIMMEL C, Pose RM, Wenzel M, Tian Z, et al
    Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort.
    Eur Urol. 2021;80:400-404.
    PubMed     Abstract available


    September 2021
  395. VICKERS AJ
    Reply to Francesco Montorsi, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. In press. https://doi.o
    Eur Urol. 2021 Sep 29. pii: S0302-2838(21)02050.
    PubMed    


  396. MONTORSI F, Gandaglia G, Briganti A
    Re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.06.026.
    Eur Urol. 2021 Sep 28. pii: S0302-2838(21)02051.
    PubMed    


  397. REN S, Yang B, Wang D
    Re: Vicenc Ruiz de Porras, Xieng C. Wang, Luis Palomero, et al. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Eur Urol 2021;79:722-33.
    Eur Urol. 2021 Sep 25. pii: S0302-2838(21)02018.
    PubMed    


  398. TRELLES CR, Martinez-Pineiro L
    Re: The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry.
    Eur Urol. 2021 Sep 24. pii: S0302-2838(21)02000.
    PubMed    


  399. HAGENS MJ, van Leeuwen PJ
    A Future Prebiopsy Imaging-guided Pathway to Safely Omit Systematic Biopsies and Prevent Diagnosis of Indolent Prostate Cancer.
    Eur Urol. 2021 Sep 21. pii: S0302-2838(21)02002.
    PubMed    


  400. LANTZ A, Bock D, Akre O, Angenete E, et al
    Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up.
    Eur Urol. 2021 Sep 15. pii: S0302-2838(21)01928.
    PubMed     Abstract available


  401. GHALI F, Kane CJ
    Re: Association of Black Race with Prostate Cancer-specific and Other-cause Mortality.
    Eur Urol. 2021 Sep 14. pii: S0302-2838(21)01999.
    PubMed    


  402. ALAN MCNEILL S, Gallagher KM, Clyde D
    Re: A Biochemical Definition of Cure After Brachytherapy for Prostate Cancer.
    Eur Urol. 2021 Sep 13. pii: S0302-2838(21)01995.
    PubMed    


  403. SHOAG JE, Hill A, Jung JH, Spratt D, et al
    Re: Safety and Efficacy of Virtual Prostatectomy with Single-dose Radiotherapy in Patients with Intermediate-risk Prostate Cancer: Results from the PROSINT Phase 2 Randomized Clinical Trial.
    Eur Urol. 2021 Sep 10. pii: S0302-2838(21)01988.
    PubMed    


  404. KWAN EM, Spain L, Anton A, Gan CL, et al
    Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
    Eur Urol. 2021 Sep 4. pii: S0302-2838(21)01979.
    PubMed     Abstract available


  405. THURTLE D, Jenkins V, Freeman A, Pearson M, et al
    Clinical Impact of the Predict Prostate Risk Communication Tool in Men Newly Diagnosed with Nonmetastatic Prostate Cancer: A Multicentre Randomised Controlled Trial.
    Eur Urol. 2021 Sep 4. pii: S0302-2838(21)01933.
    PubMed     Abstract available


  406. HOPSTAKEN JS, Bomers JGR, Sedelaar MJP, Valerio M, et al
    An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?
    Eur Urol. 2021 Sep 3. pii: S0302-2838(21)01949.
    PubMed     Abstract available


  407. LIU W, Zukotynski K, Bauman G
    Re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-
    Eur Urol. 2021;80:e77-e78.
    PubMed    


    August 2021
  408. EMMETT L, Buteau J, Papa N, Moon D, et al
    The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
    Eur Urol. 2021 Aug 28. pii: S0302-2838(21)01946.
    PubMed     Abstract available


  409. VAN POPPEL H, Roobol MJ, Chapple CR, Catto JWF, et al
    Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
    Eur Urol. 2021 Aug 15. pii: S0302-2838(21)01927.
    PubMed     Abstract available


  410. LORENTE D, Llacer C, Lozano R, de Velasco G, et al
    Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
    Eur Urol. 2021 Aug 6. pii: S0302-2838(21)01917.
    PubMed     Abstract available


  411. VENTIMIGLIA E, Pozzi E, Alfano M, Montorsi F, et al
    Re: Scott D. Lundy, Naseer Sangwan, Neel V. Parekh, et al. Functional and Taxonomic Dysbiosis of the Gut, Urine, and Semen Microbiomes in Male Infertility. Eur Urol 2021;79:826-36.
    Eur Urol. 2021;80:e53-e54.
    PubMed    


  412. GUPTA S, Pitel BA, Knight SM, Halling KC, et al
    Re: Stanley Weng, Renzo G. DiNatale, Andrew Silagy, et al. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. Eur Urol 2021;79:468-77.
    Eur Urol. 2021;80:e62-e63.
    PubMed    


  413. LUNDY SD, Vij SC, Eng C
    Reply to Eugenio Ventimiglia, Edoardo Pozzi, Massimo Alfano, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Scott D. Lundy, Naseer Sangwan, Neel V. Parekh, et al. Functional and Taxonomic Dysbiosis of the Gut, Urine, and Semen Micro
    Eur Urol. 2021;80:e55-e56.
    PubMed    


  414. MEIJER D, van Leeuwen PJ, Roberts MJ, Siriwardana AR, et al
    External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study.
    Eur Urol. 2021;80:234-242.
    PubMed     Abstract available


  415. ROBINSON AG, Izard JP, Vera-Badillo FE
    Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP.
    Eur Urol. 2021;80:123-126.
    PubMed     Abstract available


  416. WAGASKAR VG, Mittal A, Sobotka S, Ratnani P, et al
    Hood Technique for Robotic Radical Prostatectomy-Preserving Periurethral Anatomical Structures in the Space of Retzius and Sparing the Pouch of Douglas, Enabling Early Return of Continence Without Compromising Surgical Margin Rates.
    Eur Urol. 2021;80:213-221.
    PubMed     Abstract available


    July 2021
  417. HADASCHIK B, Herrmann K
    Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2021 Jul 23. pii: S0302-2838(21)01885.
    PubMed    


  418. VICKERS AJ
    Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer.
    Eur Urol. 2021 Jul 19. pii: S0302-2838(21)01867.
    PubMed     Abstract available


  419. STERNBERG CN, Castellano D, de Bono J, Fizazi K, et al
    Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Eur Urol. 2021 Jul 14. pii: S0302-2838(21)01862.
    PubMed     Abstract available


  420. ATTARD G, Brown LC, Clarke NW, Parmar MKB, et al
    Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial.
    Eur Urol. 2021 Jul 14. pii: S0302-2838(21)01864.
    PubMed    


  421. SUPIOT S, Vaugier L, Pasquier D, Buthaud X, et al
    OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
    Eur Urol. 2021 Jul 8. pii: S0302-2838(21)01816.
    PubMed     Abstract available


  422. MARSDEN T, Ahmed HU, Emberton M
    An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imaging-based diagnostic pathway with donation of tissue, blood, an
    Eur Urol. 2021 Jul 1. pii: S0302-2838(21)01817.
    PubMed     Abstract available


  423. BERGOUGNOUX A, Ea V, Paris F, Kalfa N, et al
    Reply to Zhongzhong Chen, Hua Xie, and Fang Chen's Letter to the Editor re: Vuthy Ea, Anne Bergougnoux, Pascal Philibert, et al. How Far Should We Explore Hypospadias? Next-generation Sequencing Applied to a Large Cohort of Hypospadiac Patients. Eur U
    Eur Urol. 2021;80:e12-e13.
    PubMed    


  424. CHEN Z, Xie H, Chen F
    Re: Vuthy Ea, Anne Bergougnoux, Pascal Philibert, et al. How Far Should We Explore Hypospadias? Next-generation Sequencing Applied to a Large Cohort of Hypospadiac Patients. Eur Urol 2021;79:507-515.
    Eur Urol. 2021;80:e10-e11.
    PubMed    


    June 2021
  425. SATAPATHY S, Das N, Sood A, Goyal S, et al
    Short-course (177)Lu-PSMA-617 Radioligand Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer: Time to Take the Leap?
    Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01818.
    PubMed    


  426. SHARMA V, Karnes RJ
    Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.
    Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01806.
    PubMed    


  427. GLICKSMAN RM, Berlin A
    Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospect
    Eur Urol. 2021 Jun 19. pii: S0302-2838(21)01810.
    PubMed    


  428. CIMADAMORE A, Cheng L, Lopez-Beltran A, Scarpelli M, et al
    Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma o
    Eur Urol. 2021 Jun 17. pii: S0302-2838(21)01807.
    PubMed    


  429. WILKINSON S, Ye H, Lis RT, Sowalsky AG, et al
    Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance
    Eur Urol. 2021 Jun 17. pii: S0302-2838(21)01808.
    PubMed    


  430. GHADJAR P, Hayoz S, Bernhard J, Zwahlen DR, et al
    Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.
    Eur Urol. 2021 Jun 14. pii: S0302-2838(21)01802.
    PubMed     Abstract available


  431. TILKI D, Evans CP
    Re: Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer.
    Eur Urol. 2021 Jun 9. pii: S0302-2838(21)01805.
    PubMed    


  432. SUMANASURIYA S, Seed G, Parr H, Christova R, et al
    Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
    Eur Urol. 2021 Jun 5. pii: S0302-2838(21)01799.
    PubMed     Abstract available


  433. CHOW AK, Vourganti S, Konety BR
    Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer.
    Eur Urol. 2021 Jun 3. pii: S0302-2838(21)01796.
    PubMed    


  434. CIMADAMORE A, Lopez-Beltran A, Scarpelli M, Montironi R, et al
    Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91.
    Eur Urol. 2021;79:e172-e173.
    PubMed    


  435. JONES TD, Cheng L
    Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Sys
    Eur Urol. 2021;79:e174-e175.
    PubMed    


  436. GUO C, Crespo M, Gurel B, Dolling D, et al
    CD38 in Advanced Prostate Cancers.
    Eur Urol. 2021;79:736-746.
    PubMed     Abstract available


  437. STOLZENBURG JU, Holze S, Neuhaus P, Kyriazis I, et al
    Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01).
    Eur Urol. 2021;79:750-759.
    PubMed     Abstract available


  438. EGAN J, Marhamati S, Carvalho FLF, Davis M, et al
    Retzius-sparing Robot-assisted Radical Prostatectomy Leads to Durable Improvement in Urinary Function and Quality of Life Versus Standard Robot-assisted Radical Prostatectomy Without Compromise on Oncologic Efficacy: Single-surgeon Series and Step-by-
    Eur Urol. 2021;79:839-857.
    PubMed     Abstract available


    May 2021
  439. SATISH P, Simpson B, Freeman A, Giganti F, et al
    Mapping Contemporary Biopsy Zones to Traditional Prostatic Anatomy: The Key to Understanding Relationships Between Prostate Cancer Topography, Magnetic Resonance Imaging Conspicuity, and Clinical Risk.
    Eur Urol. 2021 May 28. pii: S0302-2838(21)00355.
    PubMed    


  440. LIAUW SL
    High-risk Prostate Cancer Treated with Radiation Therapy: Opportunities to Reduce Cancer Mortality after Biochemical Failure.
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00392.
    PubMed    


  441. PADHANI AR, Rouviere O, Schoots IG
    Magnetic Resonance Imaging for Tailoring the Need to Biopsy During Follow-up for Men on Active Surveillance for Prostate Cancer.
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00393.
    PubMed    


  442. SWEENEY CJ, Martin AJ, Stockler MR, Begbie S, et al
    Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
    Eur Urol. 2021 May 21. pii: S0302-2838(21)00354.
    PubMed     Abstract available


  443. XU J, Isaacs WB
    Incorporation of Polygenic Risk Score into Guidelines for Inherited Risk Assessment for Prostate Cancer.
    Eur Urol. 2021 May 20. pii: S0302-2838(21)00323.
    PubMed    


  444. RAJWA P, Pradere B, Quhal F, Mori K, et al
    Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.
    Eur Urol. 2021 May 18. pii: S0302-2838(21)00325.
    PubMed     Abstract available


  445. PHILIPSON RG, Romero T, Wong JK, Stish BJ, et al
    Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
    Eur Urol. 2021 May 10. pii: S0302-2838(21)00314.
    PubMed     Abstract available


  446. CHENG HH
    Molecular Subtyping in the Neoadjuvant Setting in Prostate Cancer: Envisioning the Possibilities.
    Eur Urol. 2021 May 7. pii: S0302-2838(21)00308.
    PubMed    


  447. VAN POPPEL H, Hogenhout R, Albers P, van den Bergh RCN, et al
    Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, Renee Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European C
    Eur Urol. 2021 May 5. pii: S0302-2838(21)00297.
    PubMed    


  448. VAN DEN BROECK T, Oprea-Lager D, Moris L, Kailavasan M, et al
    A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer.
    Eur Urol. 2021 May 4. pii: S0302-2838(21)00298.
    PubMed     Abstract available


  449. EVANGELISTA L, Lopci E
    Re: Hendrik Van Poppel, Renee Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 2021;79:327-9: Early Detection of Prostate Canc
    Eur Urol. 2021 May 1. pii: S0302-2838(21)00296.
    PubMed    


  450. DARST BF, Sheng X, Eeles RA, Kote-Jarai Z, et al
    Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk.
    Eur Urol. 2021 May 1. pii: S0302-2838(21)00253.
    PubMed     Abstract available


  451. REITBLAT C, Bain PA, Porter ME, Bernstein DN, et al
    Value-Based Healthcare in Urology: A Collaborative Review.
    Eur Urol. 2021;79:571-585.
    PubMed     Abstract available


  452. SUNDAHL N, Gillessen S, Sweeney C, Ost P, et al
    When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities.
    Eur Urol. 2021;79:565-567.
    PubMed     Abstract available


    April 2021
  453. KIM SE, Shin JI, Shoag JE
    Re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010.
    Eur Urol. 2021 Apr 30. pii: S0302-2838(21)00251.
    PubMed    


  454. VALLE LF, Kishan AU
    Reply to Sungeun Kim, Jae Il Shin, and Jonathan Evan Shoag's Letter to the Editor re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MAST
    Eur Urol. 2021 Apr 29. pii: S0302-2838(21)00250.
    PubMed    


  455. BERCHUCK JE, Zhang Z, Silver R, Kwak L, et al
    Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
    Eur Urol. 2021 Apr 19. pii: S0302-2838(21)00237.
    PubMed     Abstract available


  456. ADELEKE S, Haroon A, Kasivisvanathan V
    Re: [(177)Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients with Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial.
    Eur Urol. 2021 Apr 16. pii: S0302-2838(21)00245.
    PubMed    


  457. CHU CE, Alshalalfa M, Sjostrom M, Zhao SG, et al
    Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00215.
    PubMed     Abstract available


  458. SADAGHIANI MS, Sheikhbahaei S, Werner RA, Pienta KJ, et al
    A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00175.
    PubMed     Abstract available


  459. PIAZZA P, Rosiello G, Chacon VT, Puliatti S, et al
    Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center.
    Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00229.
    PubMed     Abstract available


  460. OKE O, Ranasinghe W, Tang C, Shaaban S, et al
    Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma.
    Eur Urol. 2021 Apr 3. pii: S0302-2838(21)00228.
    PubMed    


  461. FICARRA V, Rossanese M, Crestani A, Alario G, et al
    Robot-assisted Radical Prostatectomy Using the Novel Urethral Fixation Technique Versus Standard Vesicourethral Anastomosis.
    Eur Urol. 2021;79:530-536.
    PubMed     Abstract available


  462. GIGANTI F, Kasivisvanathan V, Allen C, Moore CM, et al
    The Importance of Being PRECISE in Prostate Magnetic Resonance Imaging and Active Surveillance.
    Eur Urol. 2021;79:560-563.
    PubMed    


  463. HAMILTON RJ, Ding K, Crook JM, O'Callaghan CJ, et al
    The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.
    Eur Urol. 2021;79:446-452.
    PubMed     Abstract available


  464. KNIPPER S, Ascalone L, Ziegler B, Hohenhorst JL, et al
    Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy.
    Eur Urol. 2021;79:537-544.
    PubMed     Abstract available


  465. GIANNARINI G, Valotto C, Girometti R, Dal Moro F, et al
    Measuring the Quality of Diagnostic Prostate Magnetic Resonance Imaging: A Urologist's Perspective.
    Eur Urol. 2021;79:440-441.
    PubMed     Abstract available


    March 2021
  466. MOSCHOVAS MC, Bhat S, Sandri M, Rogers T, et al
    Comparing the Approach to Radical Prostatectomy Using the Multiport da Vinci Xi and da Vinci SP Robots: A Propensity Score Analysis of Perioperative Outcomes.
    Eur Urol. 2021;79:393-404.
    PubMed     Abstract available


  467. LENFANT L, Garisto J, Sawczyn G, Wilson CA, et al
    Robot-assisted Radical Prostatectomy Using Single-port Perineal Approach: Technique and Single-surgeon Matched-paired Comparative Outcomes.
    Eur Urol. 2021;79:384-392.
    PubMed     Abstract available


    February 2021
  468. ROSIELLO G, Piazza P, Tames V, Farinha R, et al
    The Impact of Previous Prostate Surgery on Surgical Outcomes for Patients Treated with Robot-assisted Radical Cystectomy for Bladder Cancer.
    Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00149.
    PubMed     Abstract available


  469. RANASINGHE W, Shapiro DD, Hwang H, Wang X, et al
    Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.
    Eur Urol. 2021;79:298-306.
    PubMed     Abstract available


  470. HU JC, Basourakos SP, Futterer J
    Need for Systematic Magnetic Resonance Imaging Interpretation and Reporting after Partial Prostate Gland Ablation.
    Eur Urol. 2021;79:167-169.
    PubMed     Abstract available


    January 2021
  471. VAN DIJK N, Gomez de Liano Lista A, Szabados B, Powles T, et al
    Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gomez de Liano Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-P
    Eur Urol. 2021;79:e20-e21.
    PubMed    


  472. KYPRIANOU N
    Re: Regenerative Potential of Prostate Luminal Cells Revealed by Single-cell Analysis.
    Eur Urol. 2021;79:161-162.
    PubMed    


  473. MORGANS AK
    Minimizing Risk to Maximize Outcomes.
    Eur Urol. 2021;79:54-55.
    PubMed    


  474. CHEN Y, Wang Z, Liu J
    Re: Giovanni Lavorgna, Riccardo Vago, Francesco Montorsi, Andrea Salonia. Surnames in Y-Chromosome-related Diseases: A New Tool for the Urologist? Eur Urol 2020;77:767-8.
    Eur Urol. 2021;79:e37.
    PubMed    


  475. DELL'OGLIO P, Meershoek P, Maurer T, Wit EMK, et al
    A DROP-IN Gamma Probe for Robot-assisted Radioguided Surgery of Lymph Nodes During Radical Prostatectomy.
    Eur Urol. 2021;79:124-132.
    PubMed     Abstract available


  476. STAVRINIDES V, Syer T, Hu Y, Giganti F, et al
    False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naive Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.
    Eur Urol. 2021;79:20-29.
    PubMed     Abstract available


    November 2020
  477. IYER G, Bochner BH, Van Allen EM, Solit DB, et al
    Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eu
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30865.
    PubMed    


  478. BECKER REN, Baras A, Bivalacqua TJ
    Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicato
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30864.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.